<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Res Pract Thromb Haemost</journal-id>
<journal-id journal-id-type="iso-abbrev">Res Pract Thromb Haemost</journal-id>
<journal-id journal-id-type="doi">10.1002/(ISSN)2475-0379</journal-id>
<journal-id journal-id-type="publisher-id">RTH2</journal-id>
<journal-title-group>
<journal-title>Research and Practice in Thrombosis and Haemostasis</journal-title>
</journal-title-group>
<issn pub-type="epub">2475-0379</issn>
<publisher>
<publisher-name>John Wiley and Sons Inc.</publisher-name>
<publisher-loc>Hoboken</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31624776</article-id>
<article-id pub-id-type="pmc">6781926</article-id>
<article-id pub-id-type="doi">10.1002/rth2.12239</article-id>
<article-id pub-id-type="publisher-id">RTH212239</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Review Article</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Review Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Blood platelet research in autism spectrum disorders: In search of biomarkers</article-title>
<alt-title alt-title-type="left-running-head">PADMAKUMAR et al.</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" id="rth212239-cr-0001">
<name>
<surname>Padmakumar</surname>
<given-names>Manisha</given-names>
</name>
<degrees>PhD</degrees>
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1138-0999</contrib-id>
<address>
<ext-link ext-link-type="uri" xlink:href="https://twitter.com/ManishaPadmaku1">@ManishaPadmaku1</ext-link>
</address>
<xref ref-type="aff" rid="rth212239-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="rth212239-cr-0002">
<name>
<surname>Van Raes</surname>
<given-names>Eveline</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="rth212239-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="rth212239-cr-0003">
<name>
<surname>Van Geet</surname>
<given-names>Chris</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="rth212239-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" id="rth212239-cr-0004">
<name>
<surname>Freson</surname>
<given-names>Kathleen</given-names>
</name>
<degrees>PhD</degrees>
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4381-2442</contrib-id>
<xref ref-type="aff" rid="rth212239-aff-0001">
<sup>1</sup>
</xref>
<address>
<email>kathleen.freson@med.kuleuven.be</email>
<ext-link ext-link-type="uri" xlink:href="https://twitter.com/kathleenfreson">@kathleenfreson</ext-link>
</address>
</contrib>
</contrib-group>
<aff id="rth212239-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Cardiovascular Sciences</named-content>
<named-content content-type="organisation-division">Center for Molecular and Vascular Biology</named-content>
<institution>KU Leuven</institution>
<named-content content-type="city">Leuven</named-content>
<country country="BE">Belgium</country>
</aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break></break>
Kathleen Freson, Center for Molecular and Vascular Biology, Leuven, Belgium<break></break>
Email: <email>kathleen.freson@med.kuleuven.be</email><break></break></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>16</day>
<month>7</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<month>10</month>
<year>2019</year>
</pub-date>
<volume>3</volume>
<issue>4</issue>
<issue-id pub-id-type="doi">10.1002/rth2.v3.4</issue-id>
<fpage>566</fpage>
<lpage>577</lpage>
<history>
<date date-type="received">
<day>02</day>
<month>4</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>03</day>
<month>6</month>
<year>2019</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2019 International Society on Thrombosis and Haemostasis <copyright-statement>-->
<copyright-statement content-type="article-copyright">© 2019 The Authors. <italic>Research and Practice in Thrombosis and Haemostasis</italic> published by Wiley Periodicals, Inc on behalf of International Society on Thrombosis and Haemostasis.</copyright-statement>
<license license-type="creativeCommonsBy-nc-nd">
<license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="file:RTH2-3-566.pdf" xlink:type="simple"></self-uri>
<abstract id="rth212239-abs-0001">
<title>Abstract</title>
<p>Autism spectrum disorder (<styled-content style="fixed-case">ASD</styled-content>) is a clinically heterogeneous neurodevelopmental disorder that is caused by gene‐environment interactions. To improve its diagnosis and treatment, numerous efforts have been undertaken to identify reliable biomarkers for autism. None of them have delivered the holy grail that represents a reproducible, quantifiable, and sensitive biomarker. Though blood platelets are mainly known to prevent bleeding, they also play pivotal roles in cancer, inflammation, and neurological disorders. Platelets could serve as a peripheral biomarker or cellular model for autism as they share common biological and molecular characteristics with neurons. In particular, platelet‐dense granules contain neurotransmitters such as serotonin and gamma‐aminobutyric acid. Molecular players controlling granule formation and secretion are similarly regulated in platelets and neurons. The major platelet integrin receptor α<styled-content style="fixed-case">II</styled-content>bβ3 has recently been linked to <styled-content style="fixed-case">ASD</styled-content> as a regulator of serotonin transport. Though many studies revealed associations between platelet markers and <styled-content style="fixed-case">ASD</styled-content>, there is an important knowledge gap in linking these markers with autism and explaining the altered platelet phenotypes detected in autism patients. The present review enumerates studies of different biomarkers detected in <styled-content style="fixed-case">ASD</styled-content> using platelets and highlights the future needs to bring this research to the next level and advance our understanding of this complex disorder.</p>
</abstract>
<kwd-group kwd-group-type="author-generated">
<kwd id="rth212239-kwd-0001">autism spectrum disorders</kwd>
<kwd id="rth212239-kwd-0002">blood platelets</kwd>
<kwd id="rth212239-kwd-0003">gamma‐aminobutyric acid</kwd>
<kwd id="rth212239-kwd-0004">integrin αIIbβ3</kwd>
<kwd id="rth212239-kwd-0005">melatonin</kwd>
<kwd id="rth212239-kwd-0006">neurotransmitter agents</kwd>
<kwd id="rth212239-kwd-0007">platelet dense granules</kwd>
<kwd id="rth212239-kwd-0008">serotonin</kwd>
</kwd-group>
<counts>
<fig-count count="2"></fig-count>
<table-count count="2"></table-count>
<page-count count="12"></page-count>
<word-count count="8883"></word-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>component-id</meta-name>
<meta-value>rth212239</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>October 2019</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.7.0 mode:remove_FC converted:08.10.2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<p content-type="self-citation">
<mixed-citation id="rth212239-cit-1001" publication-type="journal">
<string-name>
<surname>Padmakumar</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Van Raes</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Van Geet</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Freson</surname>
<given-names>K</given-names>
</string-name>. <article-title>Blood platelet research in autism spectrum disorders: In search of biomarkers</article-title>. <source xml:lang="en"/>Res Pract Thromb Haemost. <year>2019</year>;<volume>3</volume>:<fpage>566</fpage>–<lpage>577</lpage>. <pub-id pub-id-type="doi">10.1002/rth2.12239</pub-id>;</mixed-citation>
</p>
</notes>
</front>
<body>
<p>
<boxed-text content-type="box" id="rth212239-blkfxd-0001" orientation="portrait" position="anchor"><caption><title>Essentials</title></caption><p>
<list id="rth212239-list-0001" list-type="bullet"><list-item><p>Autism spectrum disorder (ASD) is a heterogeneous and complex neurodevelopmental disorder.</p></list-item><list-item><p>Easily accessible, quantifiable, and reproducible biomarkers have not been found in ASD research.</p></list-item><list-item><p>Blood platelets and neurons contain similar molecular interactors and neurotransmitters.</p></list-item><list-item><p>Platelet‐dense granule morphology, content, and function can be useful biomarkers for ASD.</p></list-item></list>
</p></boxed-text>
</p>
<sec id="rth212239-sec-0002">
<label>1</label>
<title>INTRODUCTION TO BIOMARKER RESEARCH RELATED TO AUTISM</title>
<p>Autism spectrum disorder (ASD) comprises a group of neurodevelopmental disorders that include autism, Asperger syndrome, childhood disintegrative disorder, and pervasive developmental disorder. ASD is characterized by difficulty in social interaction, communication, and repetitive behavior patterns.<xref ref-type="ref" rid="rth212239-bib-0001">1</xref> Normally, most of the symptoms start presenting during the first 2 years of life. The prevalence of ASD has been steadily growing, and according to recent studies, it is as high as 1 in 59 children under the age of 8 in the United States <xref ref-type="ref" rid="rth212239-bib-0002">2</xref> and around 1 in 100 in the European population.<xref ref-type="ref" rid="rth212239-bib-0003">3</xref> This increasing prevalence is most probably due to improved diagnostic methods. Because early intervention can help manage symptoms and improve the quality of life, identification of physiological biomarkers aiding in the early diagnosis of ASD is very relevant. Due to the high phenotypic heterogeneity and frequent comorbidities, ASD is often classified into 2 types: syndromic ASD, in which autism occurs as a comorbidity with known clinical syndromes; and idiopathic ASD, in which the patient exhibits only classical ASD features.<xref ref-type="ref" rid="rth212239-bib-0004">4</xref>, <xref ref-type="ref" rid="rth212239-bib-0005">5</xref> Numerous studies have focused on the identification of biomarkers that would aid diagnosis and predict disease severity or evaluate treatment efficacy. A recent detailed overview of neuroimaging abnormalities and diverse metabolic and genetic biomarkers points out that though some possible candidates have been put forward, not a single highly predictive biomarker to diagnose and follow up ASD has yet been found.<xref ref-type="ref" rid="rth212239-bib-0006">6</xref> Many biomarker discovery studies try to focus on finding genetic variations linked to or causing the disorder, as it is well known that there is a high heritability in ASD, inferred from twin and family studies. These genetic studies suggest many possible contributing loci and different biological pathways underlying ASD, such as chromatin remodeling, synaptic plasticity, and neuronal connectivity.<xref ref-type="ref" rid="rth212239-bib-0007">7</xref>, <xref ref-type="ref" rid="rth212239-bib-0008">8</xref>, <xref ref-type="ref" rid="rth212239-bib-0009">9</xref>
</p>
<p>Biomarker research in ASD is complicated by the wide variability in clinical presentation within core symptoms and variables such as language, cognition, and comorbid psychiatric or other symptoms. Due to the complex nature of the disease, any causative pathway or biomarker search would inevitably require a large sample size and more in‐depth analysis of the genome. Therefore, ASD research, especially for idiopathic ASD cases, is recently more focused on using next‐generation sequencing approaches.<xref ref-type="ref" rid="rth212239-bib-0010">10</xref>, <xref ref-type="ref" rid="rth212239-bib-0011">11</xref> But with the discovery of more candidate gene variants, the genetic complexity of ASD has increased even more, and there is a scarcity of patient‐derived material or relevant human cell models to study these genes and the associated defective molecular pathways. It is impossible to obtain neurons from the central nervous system (CNS) of living subjects for ex vivo research. Gene expression and imaging studies have been performed on postmortem brains, but there are many known limitations of this method, such as post‐mortem interval, cause of death, storage procedures and biomaterial integrity.<xref ref-type="ref" rid="rth212239-bib-0012">12</xref> This has hindered research on candidate gene pathways, diagnostic biomarkers, and possible therapies for ASD. To overcome these challenges, it is still important to use alternative patient‐derived cells (blood, fibroblasts, and stem cells) or material (cerebral spinal fluid, urine, feces, serum, and plasma) to gain more insights into pathophysiology and to discover biomarkers. This review focuses on studies that have used blood platelets as a patient‐derived cell model to study ASD.</p>
</sec>
<sec id="rth212239-sec-0003">
<label>2</label>
<title>PARALLELS BETWEEN PLATELETS AND NEURONS</title>
<p>Platelets are small anucleate cell fragments circulating in the blood, originally derived from megakaryocytes in the bone marrow. While the relevance of platelet activation for blood clot formation after vascular injury is well established, more exploratory research has shown that platelets contribute to the (patho)physiological processes important for cancer, inflammation, infection, and neurological diseases.<xref ref-type="ref" rid="rth212239-bib-0013">13</xref>, <xref ref-type="ref" rid="rth212239-bib-0014">14</xref>, <xref ref-type="ref" rid="rth212239-bib-0015">15</xref>, <xref ref-type="ref" rid="rth212239-bib-0016">16</xref> The parallel between platelets and serotonergic neurons was drawn in the early 1970s.<xref ref-type="ref" rid="rth212239-bib-0017">17</xref>, <xref ref-type="ref" rid="rth212239-bib-0018">18</xref> The link with neurological disorders still mostly relates to the similarities between the platelet release reaction of stored agonists following stimulation and the neurotransmitter release following an action potential in a neuron (Figure <xref ref-type="fig" rid="rth212239-fig-0001">1</xref>).<xref ref-type="ref" rid="rth212239-bib-0019">19</xref> Platelets and neurons have a strikingly similar calcium‐dependent activation and secretion mechanism, secretory vesicles (containing neurotransmitters and activating molecules such as serotonin or 5‐hydroxytryptamine [5‐HT], dopamine, epinephrine, glutamate, gamma‐aminobutyric acid [GABA], calcium, and ADP and ATP that are secreted upon activation), 5‐HT transporters (serotonin transporter [SERT] and vesicular monoamine transporter 2 [VMAT2]), and cell surface receptors such as receptors for the listed neurotransmitters, integrin β3, ephrin, and many more.<xref ref-type="ref" rid="rth212239-bib-0019">19</xref>, <xref ref-type="ref" rid="rth212239-bib-0020">20</xref>, <xref ref-type="ref" rid="rth212239-bib-0021">21</xref> Surprisingly, certain neuron‐specific markers are expressed in platelets such as reelin and amyloid precursor protein.<xref ref-type="ref" rid="rth212239-bib-0022">22</xref> Following endocytosis of different small molecules and proteins, multivesicular bodies are involved in the formation and sorting of granules in both neurons and platelets. Mutations disrupting these cargo sorting pathways have been known to cause disorders with bleeding and neurological defects.<xref ref-type="ref" rid="rth212239-bib-0023">23</xref> Even though there are many studies reporting similarities between these cell types, existing literature knowledge cannot explain why it is so. In fact, they have different embryonic signatures, as neurons have an ectoderm origin, while platelets are formed by megakaryocytes that originate from the mesoderm.<xref ref-type="ref" rid="rth212239-bib-0020">20</xref>, <xref ref-type="ref" rid="rth212239-bib-0024">24</xref>
</p>
<fig fig-type="Figure" id="rth212239-fig-0001" orientation="portrait" position="float" xml:lang="en">
<label>Figure 1</label>
<caption>
<p>Platelets and neurons share similar features related to granule activation and secretion. Left panel shows platelets taking up 5‐<styled-content style="fixed-case">HT</styled-content> through <styled-content style="fixed-case">SERT</styled-content> and storing it in dense granules via <styled-content style="fixed-case">VMAT</styled-content>2. Platelets that are activated via diverse agonists and calcium signaling, release their dense granules including 5‐<styled-content style="fixed-case">HT</styled-content>, which is detected by 5‐<styled-content style="fixed-case">HT</styled-content> receptors for the amplification of platelet activation. The integrin receptor α<styled-content style="fixed-case">II</styled-content>bβ3 becomes activated after initial platelet activation to initiate platelet‐platelet interactions via coupling with fibrinogen. Right panel shows neurons activated via calcium signaling and the arrival of the action potential, triggering release of synaptic vesicles containing neurotransmitters such as 5‐<styled-content style="fixed-case">HT</styled-content>, which bind to the 5‐<styled-content style="fixed-case">HT</styled-content> receptors of the postsynaptic neurons to complete neurotransmission. The released 5‐<styled-content style="fixed-case">HT</styled-content> is reabsorbed by the presynaptic neuron via <styled-content style="fixed-case">SERT</styled-content> activity and transported back into synaptic vesicles through <styled-content style="fixed-case">VMAT</styled-content>2. 5HT, 5‐hydroxytryptamine; LDCV, large dense‐core vesicle; SDCV, small dense‐core vesicleSERT, serotonin transporter; <styled-content style="fixed-case">VMAT</styled-content>2, vesicular monoamine transporter 2</p>
</caption>
<graphic id="nlm-graphic-1" xlink:href="RTH2-3-566-g001"></graphic>
</fig>
<p>5‐HT mediates a wide range of neuropsychological processes. A very interesting recent review provides detailed insights into the 5‐HT metabolism in and outside the CNS.<xref ref-type="ref" rid="rth212239-bib-0025">25</xref> Mammals have 2 major sites of 5‐HT production, the brain and the gastrointestinal system, where 95% of total body 5‐HT is found in the enterochromaffin cells of the gut, from where it can be released. After its release, 5‐HT reuptake is coordinated by SERT into epithelial cells, where it is enzymatically degraded, or it enters the bloodstream, where it is transported into platelets and stored for future use. The blood‐brain barrier is considered impermeable to 5‐HT, though it is expected that peripheral 5‐HT from the gastrointestinal system is released into the blood circulation, also flowing through the brain in the vicinity of neurons.<xref ref-type="ref" rid="rth212239-bib-0025">25</xref> However, there is no evidence that peripheral 5‐HT that remains mostly stored in platelets plays any role in the brain.<xref ref-type="ref" rid="rth212239-bib-0026">26</xref>, <xref ref-type="ref" rid="rth212239-bib-0027">27</xref> Platelets do not synthesize 5‐HT, but they take it up from the circulating blood via SERT (or SLC6A4)<xref ref-type="ref" rid="rth212239-bib-0028">28</xref> to package into their dense granules via VMAT2 (or SLC18A2)<xref ref-type="ref" rid="rth212239-bib-0029">29</xref> (Figure <xref ref-type="fig" rid="rth212239-fig-0001">1</xref>). Quantification of 5‐HT levels in whole blood samples is similar to the values obtained in platelets (200‐350 μg/L), while 5‐HT plasma levels are estimated to be about 1000 times lower.<xref ref-type="ref" rid="rth212239-bib-0030">30</xref> This means that a large part of the peripheral 5‐HT, once released into the blood, will be stored in platelet‐dense granules. One of the first biomarkers for ASD was elevated blood serotonin, as discussed further in a separate section in more detail.</p>
<p>Many studies have shown that platelets are useful cells to gain insights in neurological diseases such as Parkinson disease,<xref ref-type="ref" rid="rth212239-bib-0031">31</xref>, <xref ref-type="ref" rid="rth212239-bib-0032">32</xref> Alzheimer disease,<xref ref-type="ref" rid="rth212239-bib-0033">33</xref>, <xref ref-type="ref" rid="rth212239-bib-0034">34</xref> schizophrenia,<xref ref-type="ref" rid="rth212239-bib-0024">24</xref>, <xref ref-type="ref" rid="rth212239-bib-0033">33</xref> and ASD.<xref ref-type="ref" rid="rth212239-bib-0016">16</xref>, <xref ref-type="ref" rid="rth212239-bib-0035">35</xref> A recent review by Pellerin et al<xref ref-type="ref" rid="rth212239-bib-0016">16</xref> illustrates in detail how platelets were used to study Fragile X syndrome. Despite the fact that platelets are easily accessible blood cells and have diverse structural and functional similarities with neurons, studies using platelets in ASD research are rather limited (except for the numerous studies that performed 5‐HT measurements). This is probably due to the specialized nature of the in vitro tests used to evaluate platelet function, as typically performed in clinical hemostasis labs for patients with bleeding disorders. Their use is limited for patients who do not have an obvious bleeding tendency, and the expertise required is not available in most ASD research groups. For this review providing an overview of platelet studies performed for ASD, a PubMed search was performed using following search parameters: “platelet OR platelets AND autism NOT PECAM NOT Platelet Factor 4.” This resulted in 165 publications until the end of 2018 (Figure <xref ref-type="fig" rid="rth212239-fig-0002">2</xref>). By removing PECAM and platelet factor 4 in the search terms, only 4 publications were excluded, and they did not contain data in support of the hypothesis that platelets can mimic the neuronal defects causing ASD. On the basis of these selected publications, this review provides an overview of our current knowledge related to platelets and autism. We also discuss the perspectives of using this cell type as a biomarker for ASD.</p>
<fig fig-type="Figure" id="rth212239-fig-0002" orientation="portrait" position="float" xml:lang="en">
<label>Figure 2</label>
<caption>
<p>PubMed search data for platelet studies related to autism. The number of studies in an interval of 10 years were plotted from 1970 to 2018. All platelet studies in autism were retrieved using the keywords “platelet <styled-content style="fixed-case">OR</styled-content> platelets <styled-content style="fixed-case">AND</styled-content> autism <styled-content style="fixed-case">NOT PECAM NOT</styled-content> Platelet Factor 4” are shown in blue. All platelet studies related to the serotonin metabolism were found using the keywords “Platelet <styled-content style="fixed-case">OR</styled-content> Platelets <styled-content style="fixed-case">AND</styled-content> Autism <styled-content style="fixed-case">AND</styled-content> serotonin” are shown in red. About 80% of all platelet studies have focused on the serotonin metabolism, while only in the most recent 8 years, studies appeared that focused on the many other platelet characteristics</p>
</caption>
<graphic id="nlm-graphic-3" xlink:href="RTH2-3-566-g002"></graphic>
</fig>
</sec>
<sec id="rth212239-sec-0004">
<label>3</label>
<title>PLATELET‐DENSE GRANULES AND AUTISM</title>
<p>Platelets contain 2 types of specialized granules, alpha granules and dense granules, in addition to lysosomes (Figure <xref ref-type="fig" rid="rth212239-fig-0001">1</xref>). The more abundant alpha granules (40‐80 per platelet) are the largest (200‐500 nm) and comprise several important proteins such as fibrinogen, P‐selectin, von Willebrand factor, growth factors, and other small polypeptides.<xref ref-type="ref" rid="rth212239-bib-0036">36</xref> The smaller (~250 nm), scarcely populated (3‐9 per platelet) dense granules contain signaling molecules (ATP, ADP, calcium) and neurotransmitters, of which some are critical for secondary platelet activation.<xref ref-type="ref" rid="rth212239-bib-0020">20</xref> These dense granules and their secretion pathway have been compared to the regulated secretion in neurons.<xref ref-type="ref" rid="rth212239-bib-0020">20</xref>, <xref ref-type="ref" rid="rth212239-bib-0021">21</xref> In short, the neuronal secretion process uses mainly 2 types of secretory granules, the large dense‐core vesicles (LDCVs) and the small synaptic vesicles (SSVs) (Figure <xref ref-type="fig" rid="rth212239-fig-0001">1</xref>). The LDCVs contain a variety of proteins, including slow‐acting neuropeptides, growth factors, amines, and hormones and could be compared to alpha granules in platelets. However, the content of LDCVs in neurons and alpha granules in platelets is quite different, and no striking homology in their function or regulation has been found. A subgroup of the SSVs, the small dense‐core vesicles, are comparable to dense granules in platelets because their cores appear similarly dense in electron microscopy images and they both contain, at least in part, the same small molecules and neurotransmitters.<xref ref-type="ref" rid="rth212239-bib-0020">20</xref>, <xref ref-type="ref" rid="rth212239-bib-0021">21</xref> Therefore, it is not surprising that mainly platelet‐dense granule contents or their formation or function seem to be perturbed in ASD cases, as discussed in the next section.</p>
</sec>
<sec id="rth212239-sec-0005">
<label>4</label>
<title>PLATELET‐DENSE GRANULE MORPHOLOGY AND AUTISM</title>
<p>Alpha and dense granules are formed in megakaryocytes in the bone marrow prior to their transport into forming platelets.<xref ref-type="ref" rid="rth212239-bib-0037">37</xref> In platelets, granules can release their content following platelet activation. It is known that the BEACH (named after Beige and Chediak‐Higashi) domain‐containing proteins are important for platelet granule formation and secretion. For instance, genetic variants in <italic>NBEAL2</italic> cause gray platelet syndrome, a bleeding disorder characterized by absence of alpha granules,<xref ref-type="ref" rid="rth212239-bib-0038">38</xref> while variants in <italic>LYST</italic> cause Chediak‐Higashi syndrome, an immune disorder associated with a bleeding tendency characterized by a reduced number of dense granules.<xref ref-type="ref" rid="rth212239-bib-0039">39</xref> Together with the other BEACH domain–containing family members, these proteins are often described as playing a role in membrane dynamics and/or intracellular trafficking of endosome‐ or lysosome‐related proteins and vesicles.<xref ref-type="ref" rid="rth212239-bib-0040">40</xref> However, exactly how these roles are executed by each of these family members remains largely obscure.</p>
<p>Interestingly, <italic>NBEA</italic>, the gene for the BEACH domain–containing protein neurobeachin (NBEA), was located on the autism‐susceptible region of chromosome 13q, as identified by linkage studies.<xref ref-type="ref" rid="rth212239-bib-0041">41</xref>, <xref ref-type="ref" rid="rth212239-bib-0042">42</xref>, <xref ref-type="ref" rid="rth212239-bib-0043">43</xref> A de novo chromosomal translocation disrupting <italic>NBEA</italic> was later found in an ASD patient.<xref ref-type="ref" rid="rth212239-bib-0044">44</xref> Eight years later, Castermans et al<xref ref-type="ref" rid="rth212239-bib-0045">45</xref> showed defects in stimulated secretion of vesicles from mouse β‐TC3 cells that were depleted of NBEA. In addition, defects in platelet‐dense granule morphology were found in the ASD patient with the <italic>NBEA</italic> disruption.<xref ref-type="ref" rid="rth212239-bib-0045">45</xref> Electron microscopy showed platelets with smaller, more irregular, and differently localized dense granule cores when compared to control platelets.<xref ref-type="ref" rid="rth212239-bib-0045">45</xref>, <xref ref-type="ref" rid="rth212239-bib-0046">46</xref> This study suggested the involvement of NBEA in ASD via its function in vesicle trafficking, morphology, and secretion. Heterozygous NBEA knockout mice suggested NBEA involvement in neurotransmitter release and synaptic functioning<xref ref-type="ref" rid="rth212239-bib-0046">46</xref> and these mice also presented with defects in social behavior, conditioned fear response, spatial learning, and memory.<xref ref-type="ref" rid="rth212239-bib-0043">43</xref> Platelets from these NBEA knockout mice were smaller than controls and had abnormal dense‐core halos.<xref ref-type="ref" rid="rth212239-bib-0047">47</xref> A proteomics study further revealed that these platelets had a reduction in actin‐interacting elements, which could contribute to the cytoskeletal changes observed in the platelets.<xref ref-type="ref" rid="rth212239-bib-0047">47</xref> These studies highlight a promising avenue of using platelets to study ASD patients. Nonetheless, more studies on ASD subjects need to be performed to completely understand the role of NBEA in platelet‐dense granule secretion and function. A recent study validated <italic>NBEA</italic> as a neurodevelopmental disorder gene, but patients presented with a broader phenotypic spectrum than ASD, including early generalized epilepsy.<xref ref-type="ref" rid="rth212239-bib-0048">48</xref> Platelet studies were not performed for this cohort.</p>
</sec>
<sec id="rth212239-sec-0006">
<label>5</label>
<title>HYPERSEROTONEMIA IN AUTISM PLATELETS</title>
<p>In the search for a biomarker for ASD using platelets, the first studies appeared in the 1970s, when it was noted that platelet 5‐HT levels were higher in patients with early‐onset autism compared to controls.<xref ref-type="ref" rid="rth212239-bib-0017">17</xref>, <xref ref-type="ref" rid="rth212239-bib-0018">18</xref> By refining our PubMed search for studies focusing on the 5‐HT metabolism, it is clear that over the past 50 years, 80% of all the platelet‐based research for ASD has focused on this topic (Figure <xref ref-type="fig" rid="rth212239-fig-0002">2</xref>). To inform the readers about this field, we selected research‐based articles that each added a unique finding on top of measuring 5‐HT levels in whole blood, plasma, or platelets, and this in cohorts ranging from 17 to 292 ASD cases. These studies are introduced in Table <xref ref-type="table" rid="rth212239-tbl-0001">1</xref>, together with their main conclusion. Most of these studies actually confirmed the initial discovery and hyperserotonemia was detected in about 17% to 40% of the ASD cases using whole blood or platelets. Studies that found normal or even lower 5‐HT levels in ASD cases used small cohorts (&lt;25 cases) and plasma samples, therefore excluding platelet‐derived 5‐HT. Hyperserotonemia was found to be correlated to age; ethnicity; sex; genetic variants in genes regulating 5‐HT uptake (<italic>SLC6A4</italic>), synthesis (<italic>TPH1</italic>), or degradation (<italic>MAOA</italic> and <italic>MAOB</italic>); autoimmunity; gastrointestinal system, cognitive ability; and genetic variation in <italic>ITGB3</italic>, the gene coding for part of the important platelet activation receptor αIIbβ3 (Table <xref ref-type="table" rid="rth212239-tbl-0001">1</xref>). A recent meta‐analysis by Gabriele et al,<xref ref-type="ref" rid="rth212239-bib-0049">49</xref> comparing 22 previously established studies involving a total of 739 autism subjects and 868 controls, revealed significantly elevated 5‐HT levels in ASD cases compared to controls, and this for both whole blood (~23%) and platelet‐rich plasma (~29%) data sets. According to Gabriele et al,<xref ref-type="ref" rid="rth212239-bib-0049">49</xref> the overall sensitivity of high platelet 5‐HT in ASD is quite high (28% in whole blood and 22% in platelet‐rich plasma when compared across various studies). In another study, a combination of 5‐HT, N‐acetyl serotonin (NAS) and melatonin together, resulted in a sensitivity of 80% and specificity of 85%, when distinguishing ASD cases from controls.<xref ref-type="ref" rid="rth212239-bib-0050">50</xref> There are different methods to quantify 5‐HT. The most widely used are high‐performance liquid chromatography electrochemical detection (HPLC‐ECD) and ELISA.<xref ref-type="ref" rid="rth212239-bib-0051">51</xref>, <xref ref-type="ref" rid="rth212239-bib-0052">52</xref> Both methods are sensitive, time consuming, and expensive and give comparable results, though ELISA can be slightly more sensitive but less specific compared to HPLC‐ECD.<xref ref-type="ref" rid="rth212239-bib-0051">51</xref>, <xref ref-type="ref" rid="rth212239-bib-0053">53</xref> Therefore, most studies seem to support the hypothesis that blood and/or platelet hyperserotonemia could serve as an ASD biomarker, though more larger‐cohort studies are required.</p>
<table-wrap id="rth212239-tbl-0001" orientation="portrait" position="float" xml:lang="en">
<label>Table 1</label>
<caption>
<p>Literature review on serotonin quantifications using blood or blood‐derived substances from patients with autism</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top"></th>
<th align="left" colspan="1" rowspan="1" valign="top">Serotonin levels</th>
<th align="left" colspan="1" rowspan="1" valign="top">Number of ASD samples</th>
<th align="left" colspan="1" rowspan="1" valign="top">Blood or blood‐derived substances</th>
<th align="left" colspan="1" rowspan="1" valign="top">Study outcome</th>
<th align="left" colspan="1" rowspan="1" valign="top">References</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">Normal</td>
<td align="char" char="." colspan="1" rowspan="1">6</td>
<td align="left" colspan="1" rowspan="1">Platelets</td>
<td align="left" colspan="1" rowspan="1">Endogenous 5‐HT was slightly diminished but significant increase in platelet/mL plasma; 2‐fold higher efflux of radioactive 5‐HT from ASD patient platelets, which could indicate defective 5‐HT turnover in the brain</td>
<td align="left" colspan="1" rowspan="1">Boullin et al<xref ref-type="ref" rid="rth212239-bib-0018">18</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">Hyperserotonemia — Normal</td>
<td align="char" char="." colspan="1" rowspan="1">24</td>
<td align="left" colspan="1" rowspan="1">Whole blood</td>
<td align="left" colspan="1" rowspan="1">5‐HT level and platelet count are higher in ASD, while 5‐HT level corrected for platelet count was similar between ASD and controls</td>
<td align="left" colspan="1" rowspan="1">Ritvo et al<xref ref-type="ref" rid="rth212239-bib-0017">17</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">3</td>
<td align="left" colspan="1" rowspan="1">Hyperserotonemia</td>
<td align="char" char="." colspan="1" rowspan="1">77</td>
<td align="left" colspan="1" rowspan="1">Whole blood</td>
<td align="left" colspan="1" rowspan="1">Higher 5‐HT levels in ASD while normal in mentally retarded or cognitively impaired cases. Study points to the importance of matching for age and ethnicity</td>
<td align="left" colspan="1" rowspan="1">McBride et al<xref ref-type="ref" rid="rth212239-bib-0060">60</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">4</td>
<td align="left" colspan="1" rowspan="1">Hyposerotonemia</td>
<td align="char" char="." colspan="1" rowspan="1">10</td>
<td align="left" colspan="1" rowspan="1">Plasma</td>
<td align="left" colspan="1" rowspan="1">Lower 5‐HT levels in adults with ASD and inversely correlated with Overt Aggression Scale score</td>
<td align="left" colspan="1" rowspan="1">Spivak et al<xref ref-type="ref" rid="rth212239-bib-0090">90</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">5</td>
<td align="left" colspan="1" rowspan="1">Hyposerotonemia</td>
<td align="char" char="." colspan="1" rowspan="1">17</td>
<td align="left" colspan="1" rowspan="1">Plasma</td>
<td align="left" colspan="1" rowspan="1">Lower 5‐HT levels in mothers of ASD cases supporting the hypothesis that maternal 5‐HT would be a risk factor for ASD through effects on fetal brain development</td>
<td align="left" colspan="1" rowspan="1">Connors et al<xref ref-type="ref" rid="rth212239-bib-0091">91</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">6</td>
<td align="left" colspan="1" rowspan="1">Hyperserotonemia</td>
<td align="char" char="." colspan="1" rowspan="1">53</td>
<td align="left" colspan="1" rowspan="1">Platelets</td>
<td align="left" colspan="1" rowspan="1">Higher 5‐HT levels in 32% of ASD cases and a negative correlation with their speech development</td>
<td align="left" colspan="1" rowspan="1">Hranilovic et al<xref ref-type="ref" rid="rth212239-bib-0092">92</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">7</td>
<td align="left" colspan="1" rowspan="1">Hyperserotonemia</td>
<td align="char" char="." colspan="1" rowspan="1">109</td>
<td align="left" colspan="1" rowspan="1">Platelets</td>
<td align="left" colspan="1" rowspan="1">Higher 5‐HT levels in ASD cases and this in association with common <italic>SLC6A4</italic> and <italic>ITGB3</italic> haplotypes, each separately but also via a significant interaction between those genetic markers</td>
<td align="left" colspan="1" rowspan="1">Coutinho et al<xref ref-type="ref" rid="rth212239-bib-0093">93</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">8</td>
<td align="left" colspan="1" rowspan="1">Hyperserotonemia</td>
<td align="char" char="." colspan="1" rowspan="1">23</td>
<td align="left" colspan="1" rowspan="1">Platelets</td>
<td align="left" colspan="1" rowspan="1">Higher 5‐HT levels in 17% of PDD cases without an elevation in intestinal permeability measured by sugar absorption</td>
<td align="left" colspan="1" rowspan="1">Kemperman et al<xref ref-type="ref" rid="rth212239-bib-0094">94</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">9</td>
<td align="left" colspan="1" rowspan="1">Hyperserotonemia</td>
<td align="char" char="." colspan="1" rowspan="1">63</td>
<td align="left" colspan="1" rowspan="1">Platelets</td>
<td align="left" colspan="1" rowspan="1">Association between high 5‐HT in ASD and common variants in genes regulating 5‐HT synthesis (<italic>TPH1</italic>) and degradation (<italic>MAOA</italic>).</td>
<td align="left" colspan="1" rowspan="1">Hranilović et al<xref ref-type="ref" rid="rth212239-bib-0095">95</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">10</td>
<td align="left" colspan="1" rowspan="1">Hyperserotonemia</td>
<td align="char" char="." colspan="1" rowspan="1">50</td>
<td align="left" colspan="1" rowspan="1">Serum</td>
<td align="left" colspan="1" rowspan="1">Higher 5‐HT and autoimmunity marker anti‐myelin‐basic protein (anti‐MBP) levels in ASD but no correction between both markers</td>
<td align="left" colspan="1" rowspan="1">Mostafa et al<xref ref-type="ref" rid="rth212239-bib-0096">96</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">11</td>
<td align="left" colspan="1" rowspan="1">Normal</td>
<td align="char" char="." colspan="1" rowspan="1">23</td>
<td align="left" colspan="1" rowspan="1">Plasma</td>
<td align="left" colspan="1" rowspan="1">Normal 5‐HT levels in plasma point out that hyperserotonemia in ASD platelets results from the platelet's handling of 5‐HT and not from their increased exposure to 5‐HT</td>
<td align="left" colspan="1" rowspan="1">Anderson et al<xref ref-type="ref" rid="rth212239-bib-0097">97</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">12</td>
<td align="left" colspan="1" rowspan="1">Hyperserotonemia</td>
<td align="char" char="." colspan="1" rowspan="1">279</td>
<td align="left" colspan="1" rowspan="1">Whole blood</td>
<td align="left" colspan="1" rowspan="1">Higher whole blood 5‐HT levels in 40%, lower plasma melatonin in 51%, and higher platelet NAS in 47% of ASD cases. This study points to a disruption of the 5‐HT/NAS/melatonin pathway in ASD</td>
<td align="left" colspan="1" rowspan="1">Pagan et al<xref ref-type="ref" rid="rth212239-bib-0050">50</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">13</td>
<td align="left" colspan="1" rowspan="1">Hyperserotonemia</td>
<td align="char" char="." colspan="1" rowspan="1">20</td>
<td align="left" colspan="1" rowspan="1">Plasma</td>
<td align="left" colspan="1" rowspan="1">Higher 5‐HT levels in ASD patients and their unaffected siblings, suggesting heritability of this trait</td>
<td align="left" colspan="1" rowspan="1">Bijl et al<xref ref-type="ref" rid="rth212239-bib-0059">59</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">14</td>
<td align="left" colspan="1" rowspan="1">Hyperserotonemia</td>
<td align="char" char="." colspan="1" rowspan="1">203</td>
<td align="left" colspan="1" rowspan="1">Platelets</td>
<td align="left" colspan="1" rowspan="1">Association between high 5‐HT in male ASD cases and common variants in <italic>MAOB</italic> gene regulating 5‐HT degradation</td>
<td align="left" colspan="1" rowspan="1">Chakraborti et al<xref ref-type="ref" rid="rth212239-bib-0098">98</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">15</td>
<td align="left" colspan="1" rowspan="1">Hyperserotonemia</td>
<td align="char" char="." colspan="1" rowspan="1">82</td>
<td align="left" colspan="1" rowspan="1">Whole blood</td>
<td align="left" colspan="1" rowspan="1">Correlation between high 5‐HT in ASD and lower gastrointestinal symptoms</td>
<td align="left" colspan="1" rowspan="1">Marler et al<xref ref-type="ref" rid="rth212239-bib-0099">99</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">16</td>
<td align="left" colspan="1" rowspan="1">Hyperserotonemia</td>
<td align="char" char="." colspan="1" rowspan="1">292</td>
<td align="left" colspan="1" rowspan="1">Whole blood</td>
<td align="left" colspan="1" rowspan="1">The largest study performed to date showing higher 5‐HT levels but only in prepubertal ASD patients (42%) and this more likely in males</td>
<td align="left" colspan="1" rowspan="1">Shuffrey et al<xref ref-type="ref" rid="rth212239-bib-0100">100</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">17</td>
<td align="left" colspan="1" rowspan="1">Hyperserotonemia</td>
<td align="char" char="." colspan="1" rowspan="1">213</td>
<td align="left" colspan="1" rowspan="1">Whole blood</td>
<td align="left" colspan="1" rowspan="1">Platelet NAS has higher heritability than hyperserotonemia and lowered melatonin in ASD</td>
<td align="left" colspan="1" rowspan="1">Benabou et al<xref ref-type="ref" rid="rth212239-bib-0077">77</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">18</td>
<td align="left" colspan="1" rowspan="1">Hyperserotonemia</td>
<td align="char" char="." colspan="1" rowspan="1">181</td>
<td align="left" colspan="1" rowspan="1">Whole blood</td>
<td align="left" colspan="1" rowspan="1">Negative correlation between maternal 5‐HT levels and cognitive abilities in ASD</td>
<td align="left" colspan="1" rowspan="1">Montgomery et al<xref ref-type="ref" rid="rth212239-bib-0101">101</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">19</td>
<td align="left" colspan="1" rowspan="1">Hyperserotonemia</td>
<td align="char" char="." colspan="1" rowspan="1">176</td>
<td align="left" colspan="1" rowspan="1">Platelet rich plasma</td>
<td align="left" colspan="1" rowspan="1">A promotor SNP in <italic>ITGB3</italic> that results in enhanced promoter activity during megakaryocyte differentiation is associated with higher integrin β3 protein expression and higher platelet 5‐HT levels in ASD patients. ITGB3 is known to support SERT trafficking to the platelet membrane allowing enhanced 5‐HT uptake in platelets</td>
<td align="left" colspan="1" rowspan="1">Gabriele et al<xref ref-type="ref" rid="rth212239-bib-0063">63</xref>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="rth212239-note-0001">
<p>Abbreviations: 5‐HT, 5‐hydroxytryptamine; ASD, autism spectrum disorder; NAS, N‐acetyl serotonin; PDD, pervasive developmental disorder (part of ASD).</p>
</fn>
</table-wrap-foot>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<p>Different studies have tried to explain the mechanism behind platelet hyperserotonemia detected in ASD. Recognizing the importance of SERT in both platelets and CNS, studies were performed to assess its potential role in ASD hyperserotonemia. It was found that ASD patients express higher levels of SERT on platelet membranes while the affinity of SERT for 5‐HT remains the same, resulting in increased 5‐HT internalization.<xref ref-type="ref" rid="rth212239-bib-0054">54</xref> Coding and noncoding variants in the SERT gene <italic>SLC6A4</italic> have been identified, which are associated with elevated 5‐HT levels in ASD.<xref ref-type="ref" rid="rth212239-bib-0055">55</xref> Interestingly, transgenic mice overexpressing the coding gain‐of‐function (GOF) variant Ala56 in SERT presented with behavioral impairment and hyperserotonemia.<xref ref-type="ref" rid="rth212239-bib-0056">56</xref> Therefore, enhanced SERT on platelet membranes can account for hyperserotonemia in at least some ASD cases, but other contributing factors have also been detected. Common variants in <italic>ITGB3</italic>, which encodes the β‐chain of the platelet activation receptor integrin αIIbβ3 (glycoprotein GPIIbIIIa), have been linked to increased SERT activity and elevated blood 5‐HT levels, as discussed in more detail in the next section.<xref ref-type="ref" rid="rth212239-bib-0057">57</xref>, <xref ref-type="ref" rid="rth212239-bib-0058">58</xref> Another reason for whole blood hyperserotonemia could be the mildly increased platelet counts noted in some ASD studies,<xref ref-type="ref" rid="rth212239-bib-0017">17</xref>, <xref ref-type="ref" rid="rth212239-bib-0059">59</xref>, <xref ref-type="ref" rid="rth212239-bib-0060">60</xref> though this cannot explain the hyperserotonemia detected in most studies.</p>
</sec>
<sec id="rth212239-sec-0007">
<label>6</label>
<title>PLATELET ACTIVATION RECEPTOR αIIbβ3 AND AUTISM</title>
<p>Platelet‐platelet interaction during their activation is regulated via fibrinogen that binds to its membrane receptor integrin αIIbβ3. Following mild platelet activation, αIIbβ3 integrins undergo a conformational change to expose their binding site for fibrinogen (Figure <xref ref-type="fig" rid="rth212239-fig-0001">1</xref>). Numerous platelets are eventually linked by such fibrinogen bridges, resulting in a platelet plug.<xref ref-type="ref" rid="rth212239-bib-0061">61</xref>, <xref ref-type="ref" rid="rth212239-bib-0062">62</xref> As mentioned above, the β‐chain of the αIIbβ3 receptor is encoded by <italic>ITGB3</italic> and variants for this gene have been associated with elevated blood 5‐HT levels in ASD.<xref ref-type="ref" rid="rth212239-bib-0057">57</xref>, <xref ref-type="ref" rid="rth212239-bib-0063">63</xref>, <xref ref-type="ref" rid="rth212239-bib-0064">64</xref> The β3‐subunit associates with αIIb to form the integrin αIIbβ3 in platelets, and with αv to form the integrin αvβ3 in neurons.<xref ref-type="ref" rid="rth212239-bib-0065">65</xref> In platelets, activated integrin αIIbβ3 interacts directly with the C‐terminus of SERT and enhances the externalization and function of SERT.<xref ref-type="ref" rid="rth212239-bib-0066">66</xref> Similarly, in the midbrain and cortical neurons, integrin αvβ3 was also observed to be involved in the regulation of SERT.<xref ref-type="ref" rid="rth212239-bib-0067">67</xref> Preliminary data from Carter et al<xref ref-type="ref" rid="rth212239-bib-0068">68</xref> showed that <italic>Itgb3</italic> knockout mice were found to have altered social and repetitive behavior patterns, and they did not show interest toward social novelty. Such behavioral defect has not been validated in patients with Glanzmann thrombasthenia with inactivating variants in <italic>ITGB3</italic>, according to the literature.<xref ref-type="ref" rid="rth212239-bib-0061">61</xref>, <xref ref-type="ref" rid="rth212239-bib-0069">69</xref> These patients have a recessive bleeding disorder with absent platelet aggregation responses to most agonists, but ASD phenotypes have never been reported for these patients.<xref ref-type="ref" rid="rth212239-bib-0061">61</xref> Severe psychomotor retardation was reported in only a single patient with Glanzmann thrombasthenia in combination with tuberous sclerosis, which is a multisystemic disorder, sometimes presenting with ASD.<xref ref-type="ref" rid="rth212239-bib-0070">70</xref> Interestingly, a recent study showed that a variant in the <italic>ITGB3</italic> gene promoter is associated with enhanced promoter activity in megakaryocytes, higher β3‐subunit expression in platelets, enhanced expression of SERT on the plasma membrane, and elevated 5‐HT levels in blood from ASD cases.<xref ref-type="ref" rid="rth212239-bib-0063">63</xref> This would mean that ASD is not associated with inactivating but rather GOF variants in <italic>ITGB3</italic>, probably explaining the absence of obvious autism phenotypes in patients with Glanzmann thrombasthenia. However, a case report with a GOF variant in <italic>ITGB3</italic> was reported with bleeding symptoms and mild thrombocytopenia, but a neurological phenotype was not reported.<xref ref-type="ref" rid="rth212239-bib-0071">71</xref> Platelets from this patient showed enhanced fibrinogen binding but also low αIIbβ3 expression levels, and this probably will not result in enhanced SERT expression on the platelet membrane, though it was not studied. Further studies are needed that focus on the role of this important platelet activation receptor in neuropathology.</p>
</sec>
<sec id="rth212239-sec-0008">
<label>7</label>
<title>PLATELET FUNCTION, COUNT, AND SIZE STUDIES IN AUTISM</title>
<p>Using a light‐transmission aggregometer, platelets are activated by adding an agonist such as ADP, collagen, thrombin, epinephrine or thromboxane A2 analog (U46619) that boosts platelet‐platelet interactions and the release of their granules to achieve a full activation response<xref ref-type="ref" rid="rth212239-bib-0020">20</xref>, <xref ref-type="ref" rid="rth212239-bib-0072">72</xref> (Figure <xref ref-type="fig" rid="rth212239-fig-0001">1</xref>). Table <xref ref-type="table" rid="rth212239-tbl-0002">2</xref> presents the few studies that have performed platelet activation studies for ASD. In 1988, platelet aggregations were performed for children with infantile autism, and a consistent, though not significant, trend of lower platelet responses was detected after activation with collagen and ADP.<xref ref-type="ref" rid="rth212239-bib-0073">73</xref> About 20 years later, a study showed a borderline significant decrease in ADP‐induced platelet aggregation for ASD cases with normal but not increased platelet 5‐HT levels.<xref ref-type="ref" rid="rth212239-bib-0074">74</xref> Recently, detailed platelet function studies were performed for a larger cohort of 159 idiopathic ASD cases and their first‐degree relatives.<xref ref-type="ref" rid="rth212239-bib-0059">59</xref> Though the maximal platelet aggregation response to epinephrine was not lower for ASD cases, its secondary wave response, which is dependent on dense granule secretion, was more frequently delayed or absent in ASD cases compared to controls. In addition, stimulated release of ATP from dense granules was reduced in ASD cases and their first‐degree relatives compared to unrelated controls following activation with ADP and collagen.<xref ref-type="ref" rid="rth212239-bib-0059">59</xref> These findings suggest that at least for a subgroup of ASD cases, platelet granule secretion and subsequent activation is impaired, but it was not clear if this observation is linked to defects in 5‐HT uptake or release. Again, larger cohort studies are required to validate platelet functional parameters. Other platelet parameters such as their size (mean platelet volume) and count are not widely studied. Bijl et al<xref ref-type="ref" rid="rth212239-bib-0059">59</xref> reported only a mild increase in platelet count for ASD cases and their siblings.</p>
<table-wrap id="rth212239-tbl-0002" orientation="portrait" position="float" xml:lang="en">
<label>Table 2</label>
<caption>
<p>Literature review on platelet function studies in ASD patients</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">Functional platelet test</th>
<th align="left" colspan="1" rowspan="1" valign="top">Number of ASD samples</th>
<th align="left" colspan="1" rowspan="1" valign="top">Agonists</th>
<th align="left" colspan="1" rowspan="1" valign="top">Study outcome</th>
<th align="left" colspan="1" rowspan="1" valign="top">References</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Aggregation</td>
<td align="char" char="." colspan="1" rowspan="1">14</td>
<td align="left" colspan="1" rowspan="1">ADP, collagen</td>
<td align="left" colspan="1" rowspan="1">Reduced platelet aggregation with both agonists but did not reach significance due to low sample size</td>
<td align="left" colspan="1" rowspan="1">Safai‐Kutti et al<xref ref-type="ref" rid="rth212239-bib-0073">73</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Aggregation</td>
<td align="char" char="." colspan="1" rowspan="1">7</td>
<td align="left" colspan="1" rowspan="1">ADP and 5‐HT</td>
<td align="left" colspan="1" rowspan="1">Reduced 5‐HT amplified aggregation indicating a defect in platelet 5‐HT<sub>2</sub> receptor complex</td>
<td align="left" colspan="1" rowspan="1">McBridge et al<xref ref-type="ref" rid="rth212239-bib-0102">102</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Aggregation</td>
<td align="char" char="." colspan="1" rowspan="1">17</td>
<td align="left" colspan="1" rowspan="1">ADP</td>
<td align="left" colspan="1" rowspan="1">Marginally significant reduction in aggregation in ASD patients with normal platelet 5‐HT levels indicating that the platelet functional defect could be independent of the serotonergic system</td>
<td align="left" colspan="1" rowspan="1">Hranilović et al<xref ref-type="ref" rid="rth212239-bib-0074">74</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">ATP secretion</td>
<td align="char" char="." colspan="1" rowspan="1">159</td>
<td align="left" colspan="1" rowspan="1">ADP, collagen</td>
<td align="left" colspan="1" rowspan="1">Reduced stimulated release of ATP from platelets of ASD patients and first‐degree relatives indicating potentially heritable dense granule secretion defect</td>
<td align="left" colspan="1" rowspan="1">Bijl et al<xref ref-type="ref" rid="rth212239-bib-0059">59</xref>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="rth212239-note-0002">
<p>Abbreviations: 5‐HT, 5‐hydroxytryptamine; ASD, autism spectrum disorder.</p>
</fn>
</table-wrap-foot>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
</sec>
<sec id="rth212239-sec-0009">
<label>8</label>
<title>SEROTONIN DERIVATIVES N‐ACETYL SEROTONIN AND MELATONIN IN AUTISM</title>
<p>The biosynthesis of melatonin occurs following 5‐HT acetylation by the enzyme arylalkylamine N‐acetyltransferase (AANAT) to NAS, which is then methylated by acetylserotonin O‐methyltransferase (ASMT) to melatonin.<xref ref-type="ref" rid="rth212239-bib-0075">75</xref>, <xref ref-type="ref" rid="rth212239-bib-0076">76</xref> It has been shown in the literature that there is a reduction in the plasma level of melatonin in ASD cases.<xref ref-type="ref" rid="rth212239-bib-0050">50</xref> NAS is an important intermediate in the pathway of melatonin biosynthesis from 5‐HT, and it has been found to be transported to platelet‐dense granules, along with 5‐HT.<xref ref-type="ref" rid="rth212239-bib-0075">75</xref> Recent studies found increased NAS levels in ASD platelets and that this observation was more heritable in ASD families than hyperserotonemia and decreased melatonin (Table <xref ref-type="table" rid="rth212239-tbl-0001">1</xref>).<xref ref-type="ref" rid="rth212239-bib-0050">50</xref>, <xref ref-type="ref" rid="rth212239-bib-0075">75</xref>, <xref ref-type="ref" rid="rth212239-bib-0077">77</xref> Increased NAS, together with decreased melatonin, probably points to a defect in the melatonin synthesis pathway. Indeed, the activities of AANAT and ASMT, the 2 key enzymes contributing to melatonin synthesis, were reduced in postmortem samples of the pineal gland, gut, and platelets of ASD cases.<xref ref-type="ref" rid="rth212239-bib-0075">75</xref> Furthermore, it was noted that the heritability of reduction in ASMT activity was also higher than hyperserotonemia but similar to NAS.<xref ref-type="ref" rid="rth212239-bib-0077">77</xref> Melatonin has been well studied due to its use as a sleep inducer, but more recent studies have shown that NAS can regulate mood.<xref ref-type="ref" rid="rth212239-bib-0078">78</xref>, <xref ref-type="ref" rid="rth212239-bib-0079">79</xref> It has also been shown to bind to the tropomyosin receptor kinase B receptor similar to the brain‐derived neurotrophic factor, suggesting a role in neuronal growth and proliferation.<xref ref-type="ref" rid="rth212239-bib-0075">75</xref>, <xref ref-type="ref" rid="rth212239-bib-0079">79</xref> This was confirmed in hippocampal neurons in sleep‐deprived mice.<xref ref-type="ref" rid="rth212239-bib-0078">78</xref>, <xref ref-type="ref" rid="rth212239-bib-0079">79</xref> Therefore, increased platelet NAS could echo its levels in the CNS, which in turn supports an abnormal growth acceleration in neural precursor cells from ASD cases as observed in a study by Schafer et al.<xref ref-type="ref" rid="rth212239-bib-0080">80</xref> Platelet NAS should be measured in larger ASD cohorts in addition to 5‐HT to evaluate its potential as an ASD biomarker.</p>
</sec>
<sec id="rth212239-sec-0010">
<label>9</label>
<title>OTHER NEUROTRANSMITTERS STORED IN PLATELETS AND STUDIED IN AUTISM</title>
<p>There is very limited evidence of other neurotransmitter changes in platelets of ASD patients. In one of the earliest studies focused on peripheral biomarkers for autism, Lake et al<xref ref-type="ref" rid="rth212239-bib-0081">81</xref> discovered an increased level of plasma norepinephrine, which they attributed to the low activity of the enzyme dopamine β‐hydroxylase, which is responsible for the conversion of dopamine to norepinephrine. Ten years later, this observation was confirmed by another study that also detected a significant increase of epinephrine in plasma, together with a decrease in platelet epinephrine, norepinephrine, and dopamine in ASD subjects.<xref ref-type="ref" rid="rth212239-bib-0082">82</xref> Such data suggest a broader bioamine metabolism defect in ASD. Following these initial studies (performed in only 22 ASD cases), no substantial progress has been made regarding the status of these neurotransmitters in larger ASD cohorts.</p>
<p>Other platelet neurotransmitters studied in ASD are the major inhibitory neurotransmitter GABA and the major excitatory neurotransmitter glutamate. The imbalance in the excitation/inhibition pathways of these neurotransmitters has been reported in ASD.<xref ref-type="ref" rid="rth212239-bib-0083">83</xref> Platelets contain glutamate in their dense granules, which is released exclusively by activated platelets and this can enhance platelet activation.<xref ref-type="ref" rid="rth212239-bib-0084">84</xref>, <xref ref-type="ref" rid="rth212239-bib-0085">85</xref> On the other hand, platelet aggregation is influenced by GABA, which is only 30% less abundant in platelets compared to cultured neurons.<xref ref-type="ref" rid="rth212239-bib-0086">86</xref> Though these neurotransmitters are actively studied in ASD cases, studies investigating their expression or function in autism platelets, are very limited. While early studies suggested decreased levels of both GABA and glutamate in ASD platelets,<xref ref-type="ref" rid="rth212239-bib-0087">87</xref> subsequent studies have shown an elevation of plasma GABA and glutamate levels in ASD.<xref ref-type="ref" rid="rth212239-bib-0083">83</xref>, <xref ref-type="ref" rid="rth212239-bib-0088">88</xref>, <xref ref-type="ref" rid="rth212239-bib-0089">89</xref>
</p>
</sec>
<sec id="rth212239-sec-0011">
<label>10</label>
<title>FUTURE PERSPECTIVES USING PLATELETS FOR ASD RESEARCH</title>
<p>The exact pathophysiology of ASD has remained elusive over the years even though diagnostic and monitoring strategies have improved over time. This is in part due to ASD essentially being a spectrum that encompasses several disorders that seem to converge when it comes to the ASD core symptoms. Biomarkers, endophenotypes, and patient‐derived peripheral cell models can prove very useful in understanding ASD, thereby providing better stratification along the spectrum. To this end, platelet studies have shed more light on the ASD, defined by platelet hyperserotonemia. It would be interesting to determine 5‐HT and its related markers, NAS and melatonin, in very large cohort studies to study associations with diverse autism characteristics that are now all grouped under the term <italic>ASD</italic>. However, though hyperserotonemia in blood and platelets from ASD cases is a consistent observation that is over half a century old, the exact underlying mechanism deserves further molecular studies. Perhaps the answer lies in the basic biochemical properties shared by platelets and neurons, the reason behind which has never been explored in the literature. The small steps forward in this field are probably the result of the fact that blood and especially platelets are relatively foreign systems to most neuroscientists. Some initial studies have been performed to explain hyperserotonemia that have focused on genetic factors that modify SERT expression or activity to modify 5‐HT uptake by platelets as described in this review. The main question remains as to where the extra 5‐HT detected in ASD cases originates. As 95% of the total body 5‐HT is produced by the enterochromaffin cells of the gut, alterations in this metabolism could result in altered 5‐HT uptake in the blood and platelets. It would be interesting to study this in <italic>Itgb3</italic> knockout mice. Future studies combining microbiome and platelet studies in ASD cases could also provide novel insights.</p>
<p>Furthermore, studies that focus on platelet functional tests and platelet‐dense granule formation and morphology, should be undertaken for larger ASD cohorts and in animal models for known ASD genes. It would also be very interesting to know if the defects of platelet‐dense granules and hyperserotonemia in ASD are related. Due to the complex heritability of ASD, the ultimate goal would be to split all ASD cases into subgroups with a more specific endophenotype, such as having ASD with a platelet‐dense granule secretion defect, to assist the analysis of next‐generation sequencing studies for ASD gene discovery, by the selection of candidate genes related to granule biology.</p>
</sec>
<sec id="rth212239-sec-0012">
<title>RELATIONSHIP DISCLOSURE</title>
<p>The authors declare that they have no conflict of interest.</p>
</sec>
<sec id="rth212239-sec-0013">
<title>AUTHOR CONTRIBUTIONS</title>
<p>All authors contributed to writing and reviewing the article.</p>
</sec>
</body>
<back>
<ref-list content-type="cited-references" id="rth212239-bibl-0001">
<title>REFERENCES</title>
<ref id="rth212239-bib-0001">
<label>1</label>
<mixed-citation id="rth212239-cit-0001" publication-type="journal">
<string-name>
<surname>Fakhoury</surname>
<given-names>M</given-names>
</string-name>. <article-title>Autistic spectrum disorders: A review of clinical features, theories and diagnosis</article-title>. <source xml:lang="en"/>Int J Dev Neurosci. <year>2015</year>;<volume>43</volume>:<fpage>70</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">25862937</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0002">
<label>2</label>
<mixed-citation id="rth212239-cit-0002" publication-type="journal">
<string-name>
<surname>Baio</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wiggins</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Christensen</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Maenner</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Daniels</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Warren</surname>
<given-names>Z</given-names>
</string-name>, et al. <article-title>Prevalence of autism spectrum disorder among children aged 8 years — autism and developmental disabilities monitoring network, 11 sites, United States, 2014</article-title>. <source xml:lang="en"/>MMWR Surveill Summ. <year>2018</year>;<volume>67</volume>:<fpage>1</fpage>–<lpage>23</lpage>.</mixed-citation>
</ref>
<ref id="rth212239-bib-0003">
<label>3</label>
<mixed-citation id="rth212239-cit-0003" publication-type="journal">
<string-name>
<surname>Saemundsen</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Magnússon</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Georgsdóttir</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Egilsson</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Rafnsson</surname>
<given-names>V</given-names>
</string-name>. <article-title>Prevalence of autism spectrum disorders in an Icelandic birth cohort</article-title>. <source xml:lang="en"/>BMJ Open. <year>2013</year>;<volume>3</volume>:<fpage>e002748</fpage>.</mixed-citation>
</ref>
<ref id="rth212239-bib-0004">
<label>4</label>
<mixed-citation id="rth212239-cit-0004" publication-type="journal">
<string-name>
<surname>Caglayan</surname>
<given-names>AO</given-names>
</string-name>. <article-title>Genetic causes of syndromic and non‐syndromic autism</article-title>. <source xml:lang="en"/>Dev Med Child Neurol. <year>2010</year>;<volume>52</volume>:<fpage>130</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">20059518</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0005">
<label>5</label>
<mixed-citation id="rth212239-cit-0005" publication-type="journal">
<string-name>
<surname>Lintas</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Persico</surname>
<given-names>AM</given-names>
</string-name>. <article-title>Autistic phenotypes and genetic testing: state‐of‐the‐art for the clinical geneticist</article-title>. <source xml:lang="en"/>J Med Genet. <year>2009</year>;<volume>46</volume>:<fpage>1</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">18728070</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0006">
<label>6</label>
<mixed-citation id="rth212239-cit-0006" publication-type="journal">
<string-name>
<surname>Bjørklund</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Meguid</surname>
<given-names>NA</given-names>
</string-name>, <string-name>
<surname>El‐Ansary</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>El‐Bana</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Dadar</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Aaseth</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Diagnostic and severity‐tracking biomarkers for autism spectrum disorder</article-title>. <source xml:lang="en"/>J Mol Neurosci. <year>2018</year>;<volume>66</volume>:<fpage>492</fpage>–<lpage>511</lpage>.<pub-id pub-id-type="pmid">30357679</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0007">
<label>7</label>
<mixed-citation id="rth212239-cit-0007" publication-type="journal">
<string-name>
<surname>Bourgeron</surname>
<given-names>T</given-names>
</string-name>. <article-title>From the genetic architecture to synaptic plasticity in autism spectrum disorder</article-title>. <source xml:lang="en"/>Nat Rev Neurosci. <year>2015</year>;<volume>16</volume>:<fpage>551</fpage>–<lpage>63</lpage>.<pub-id pub-id-type="pmid">26289574</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0008">
<label>8</label>
<mixed-citation id="rth212239-cit-0008" publication-type="journal">
<string-name>
<surname>Gai</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Xie</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Perin</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Takahashi</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Murphy</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Wenocur</surname>
<given-names>AS</given-names>
</string-name>, et al. <article-title>Rare structural variation of synapse and neurotransmission genes in autism</article-title>. <source xml:lang="en"/>Mol Psychiatry. <year>2012</year>;<volume>17</volume>:<fpage>402</fpage>–<lpage>11</lpage>.<pub-id pub-id-type="pmid">21358714</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0009">
<label>9</label>
<mixed-citation id="rth212239-cit-0009" publication-type="journal">
<string-name>
<surname>Pinto</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Delaby</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Merico</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Barbosa</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Merikangas</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Klei</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Convergence of genes and cellular pathways dysregulated in autism spectrum disorders</article-title>. <source xml:lang="en"/>Am J Hum Genet. <year>2014</year>;<volume>94</volume>:<fpage>677</fpage>–<lpage>94</lpage>.<pub-id pub-id-type="pmid">24768552</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0010">
<label>10</label>
<mixed-citation id="rth212239-cit-0010" publication-type="journal">
<string-name>
<surname>Turner</surname>
<given-names>TN</given-names>
</string-name>, <string-name>
<surname>Coe</surname>
<given-names>BP</given-names>
</string-name>, <string-name>
<surname>Dickel</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>Hoekzema</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Nelson</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Zody</surname>
<given-names>MC</given-names>
</string-name>, et al. <article-title>Genomic patterns of de novo mutation in simplex autism</article-title>. <source xml:lang="en"/>Cell. <year>2017</year>;<volume>171</volume>:<fpage>710</fpage>–<lpage>722.e12</lpage>.<pub-id pub-id-type="pmid">28965761</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0011">
<label>11</label>
<mixed-citation id="rth212239-cit-0011" publication-type="journal">
<string-name>
<surname>Sanders</surname>
<given-names>SJ</given-names>
</string-name>. <article-title>Next‐generation sequencing in autism spectrum disorder</article-title>. <source xml:lang="en"/>Cold Spring Harb Perspect Med. <year>2018</year>; pii:<fpage>a026872</fpage>.</mixed-citation>
</ref>
<ref id="rth212239-bib-0012">
<label>12</label>
<mixed-citation id="rth212239-cit-0012" publication-type="journal">
<string-name>
<surname>Stan</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Ghose</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Gao</surname>
<given-names>X‐M</given-names>
</string-name>, <string-name>
<surname>Roberts</surname>
<given-names>RC</given-names>
</string-name>, <string-name>
<surname>Lewis‐Amezcua</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Hatanpaa</surname>
<given-names>KJ</given-names>
</string-name>, et al. <article-title>Human postmortem tissue: what quality markers matter?</article-title>
<source xml:lang="en"/>Brain Res. <year>2006</year>;<volume>1123</volume>:<fpage>1</fpage>–<lpage>11</lpage>.<pub-id pub-id-type="pmid">17045977</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0013">
<label>13</label>
<mixed-citation id="rth212239-cit-0013" publication-type="journal">
<string-name>
<surname>Marx</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Xiao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Baschin</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Splittstöhser</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Altmann</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Moritz</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>The role of platelets in cancer pathophysiology: focus on malignant glioma</article-title>. <source xml:lang="en"/>Cancers (Basel). <year>2019</year>;<volume>11</volume>:<fpage>569</fpage>.</mixed-citation>
</ref>
<ref id="rth212239-bib-0014">
<label>14</label>
<mixed-citation id="rth212239-cit-0014" publication-type="journal">
<string-name>
<surname>Speth</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Löffler</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Krappmann</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Lass‐Flörl</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Rambach</surname>
<given-names>G</given-names>
</string-name>. <article-title>Platelets as immune cells in infectious diseases</article-title>. <source xml:lang="en"/>Future Microbiol. <year>2013</year>;<volume>8</volume>:<fpage>1431</fpage>–<lpage>51</lpage>.<pub-id pub-id-type="pmid">24199802</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0015">
<label>15</label>
<mixed-citation id="rth212239-cit-0015" publication-type="journal">
<string-name>
<surname>Olumuyiwa‐Akeredolu</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Page</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Soma</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Pretorius</surname>
<given-names>E</given-names>
</string-name>. <article-title>Platelets: emerging facilitators of cellular crosstalk in rheumatoid arthritis</article-title>. <source xml:lang="en"/>Nat Rev Rheumatol. <year>2019</year>;<volume>15</volume>:<fpage>237</fpage>–<lpage>48</lpage>.<pub-id pub-id-type="pmid">30824879</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0016">
<label>16</label>
<mixed-citation id="rth212239-cit-0016" publication-type="journal">
<string-name>
<surname>Pellerin</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Lortie</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Corbin</surname>
<given-names>F</given-names>
</string-name>. <article-title>Platelets as a surrogate disease model of neurodevelopmental disorders: insights from Fragile X Syndrome</article-title>. <source xml:lang="en"/>Platelets. <year>2018</year>;<volume>29</volume>:<fpage>113</fpage>–<lpage>24</lpage>.<pub-id pub-id-type="pmid">28660769</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0017">
<label>17</label>
<mixed-citation id="rth212239-cit-0017" publication-type="journal">
<string-name>
<surname>Ritvo</surname>
<given-names>ER</given-names>
</string-name>, <string-name>
<surname>Yuwiler</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Geller</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Ornitz</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Saeger</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Plotkin</surname>
<given-names>S</given-names>
</string-name>. <article-title>Increased blood serotonin and platelets in early infantile autism</article-title>. <source xml:lang="en"/>Arch Gen Psychiatry. <year>1970</year>;<volume>23</volume>:<fpage>566</fpage>–<lpage>72</lpage>.<pub-id pub-id-type="pmid">5482649</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0018">
<label>18</label>
<mixed-citation id="rth212239-cit-0018" publication-type="journal">
<string-name>
<surname>Boullin</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Coleman</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>O'Brien</surname>
<given-names>RA</given-names>
</string-name>. <article-title>Abnormalities in platelet 5‐hydroxytryptamine efflux in patients with infantile autism</article-title>. <source xml:lang="en"/>Nature. <year>1970</year>;<volume>226</volume>:<fpage>371</fpage>–<lpage>2</lpage>.<pub-id pub-id-type="pmid">5439739</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0019">
<label>19</label>
<mixed-citation id="rth212239-cit-0019" publication-type="journal">
<string-name>
<surname>Fresh</surname>
<given-names>Ponomarev ED</given-names>
</string-name>. <article-title>Evidence for platelets as neuronal and innate immune cells: their role in the activation, differentiation, and deactivation of Th1, Th17, and Tregs during tissue inflammation</article-title>. <source xml:lang="en"/>Front Immunol. <year>2018</year>;<volume>9</volume>:<fpage>406</fpage>.<pub-id pub-id-type="pmid">29599771</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0020">
<label>20</label>
<mixed-citation id="rth212239-cit-0020" publication-type="journal">
<string-name>
<surname>Reed</surname>
<given-names>GL</given-names>
</string-name>, <string-name>
<surname>Fitzgerald</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Polgár</surname>
<given-names>J</given-names>
</string-name>. <article-title>Molecular mechanisms of platelet exocytosis: insights into the “secret” life of thrombocytes</article-title>. <source xml:lang="en"/>Blood. <year>2000</year>;<volume>96</volume>:<fpage>3334</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="pmid">11071625</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0021">
<label>21</label>
<mixed-citation id="rth212239-cit-0021" publication-type="journal">
<string-name>
<surname>Goubau</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Buyse</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Van Geet</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Freson</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Geet</surname>
<given-names>CVAN</given-names>
</string-name>, <string-name>
<surname>Freson</surname>
<given-names>K</given-names>
</string-name>. <article-title>The contribution of platelet studies to the understanding of disease mechanisms in complex and monogenetic neurological disorders</article-title>. <source xml:lang="en"/>Dev Med Child Neurol. <year>2014</year>;<volume>56</volume>(<issue>8</issue>):<fpage>724</fpage>–<lpage>31</lpage>.<pub-id pub-id-type="pmid">24579816</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0022">
<label>22</label>
<mixed-citation id="rth212239-cit-0022" publication-type="book">
<string-name>
<surname>Canobbio</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Guidetti</surname>
<given-names>GF</given-names>
</string-name>, <string-name>
<surname>Torti</surname>
<given-names>M</given-names>
</string-name>. <source xml:lang="en"/>Platelets in Neurological Disorders. Platelets in Thrombotic and Non‐Thrombotic Disorders. <publisher-loc>Cham</publisher-loc>: <publisher-name>Springer International Publishing</publisher-name>; <year>2017</year>: pp. <fpage>513</fpage>–<lpage>30</lpage>.</mixed-citation>
</ref>
<ref id="rth212239-bib-0023">
<label>23</label>
<mixed-citation id="rth212239-cit-0023" publication-type="journal">
<string-name>
<surname>Gissen</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Maher</surname>
<given-names>ER</given-names>
</string-name>. <article-title>Cargos and genes: insights into vesicular transport from inherited human disease</article-title>. <source xml:lang="en"/>J Med Genet. <year>2007</year>;<volume>44</volume>:<fpage>545</fpage>–<lpage>55</lpage>.<pub-id pub-id-type="pmid">17526798</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0024">
<label>24</label>
<mixed-citation id="rth212239-cit-0024" publication-type="journal">
<string-name>
<surname>Asor</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Ben‐Shachar</surname>
<given-names>D</given-names>
</string-name>. <article-title>Platelets: a possible glance into brain biological processes in schizophrenia</article-title>. <source xml:lang="en"/>World J Psychiatry. <year>2012</year>;<volume>2</volume>(<issue>6</issue>):<fpage>124</fpage>–<lpage>33</lpage>.<pub-id pub-id-type="pmid">24175178</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0025">
<label>25</label>
<mixed-citation id="rth212239-cit-0025" publication-type="journal">
<string-name>
<surname>Janušonis</surname>
<given-names>S</given-names>
</string-name>. <article-title>Serotonin dynamics in and around the central nervous system: is autism solvable without fundamental insights?</article-title>
<source xml:lang="en"/>Int J Dev Neurosci. <year>2014</year>;<volume>39</volume>:<fpage>9</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="pmid">24886833</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0026">
<label>26</label>
<mixed-citation id="rth212239-cit-0026" publication-type="journal">
<string-name>
<surname>Namkung</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>S</given-names>
</string-name>. <article-title>Peripheral serotonin: a new player in systemic energy homeostasis</article-title>. <source xml:lang="en"/>Mol Cells. <year>2015</year>;<volume>38</volume>:<fpage>1023</fpage>.<pub-id pub-id-type="pmid">26628041</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0027">
<label>27</label>
<mixed-citation id="rth212239-cit-0027" publication-type="journal">
<string-name>
<surname>Lv</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>F</given-names>
</string-name>. <article-title>The role of serotonin beyond the central nervous system during embryogenesis</article-title>. <source xml:lang="en"/>Front Cell Neurosci. <year>2017</year>;<volume>11</volume>:<fpage>74</fpage>.<pub-id pub-id-type="pmid">28348520</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0028">
<label>28</label>
<mixed-citation id="rth212239-cit-0028" publication-type="journal">
<string-name>
<surname>Lesch</surname>
<given-names>KP</given-names>
</string-name>, <string-name>
<surname>Wolozin</surname>
<given-names>BL</given-names>
</string-name>, <string-name>
<surname>Murphy</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Reiderer</surname>
<given-names>P</given-names>
</string-name>. <article-title>Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter</article-title>. <source xml:lang="en"/>J Neurochem. <year>1993</year>;<volume>60</volume>:<fpage>2319</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="pmid">7684072</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0029">
<label>29</label>
<mixed-citation id="rth212239-cit-0029" publication-type="journal">
<string-name>
<surname>Höltje</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Winter</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Walther</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Pahner</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Hörtnagl</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Ottersen</surname>
<given-names>OP</given-names>
</string-name>, et al. <article-title>The vesicular monoamine content regulates VMAT2 activity through Galphaq in mouse platelets. Evidence for autoregulation of vesicular transmitter uptake</article-title>. <source xml:lang="en"/>J Biol Chem. <year>2003</year>;<volume>278</volume>:<fpage>15850</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">12604601</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0030">
<label>30</label>
<mixed-citation id="rth212239-cit-0030" publication-type="journal">
<string-name>
<surname>Janusonis</surname>
<given-names>S</given-names>
</string-name>. <article-title>Origin of the blood hyperserotonemia of autism</article-title>. <source xml:lang="en"/>Theor Biol Med Model. <year>2008</year>;<volume>5</volume>:<fpage>10</fpage>.<pub-id pub-id-type="pmid">18498654</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0031">
<label>31</label>
<mixed-citation id="rth212239-cit-0031" publication-type="journal">
<string-name>
<surname>Boullin</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>O'Brien</surname>
<given-names>RA</given-names>
</string-name>. <article-title>Accumulation of dopamine by blood platelets from normal subjects and parkinsonian patients under treatment with L‐DOPA</article-title>. <source xml:lang="en"/>Br J Pharmacol. <year>1970</year>;<volume>39</volume>:<fpage>779</fpage>–<lpage>88</lpage>.<pub-id pub-id-type="pmid">5485151</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0032">
<label>32</label>
<mixed-citation id="rth212239-cit-0032" publication-type="journal">
<string-name>
<surname>Behari</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Shrivastava</surname>
<given-names>M</given-names>
</string-name>. <article-title>Role of platelets in neurodegenerative diseases: a universal pathophysiology</article-title>. <source xml:lang="en"/>Int J Neurosci. <year>2013</year>;<volume>123</volume>:<fpage>287</fpage>–<lpage>99</lpage>.<pub-id pub-id-type="pmid">23301959</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0033">
<label>33</label>
<mixed-citation id="rth212239-cit-0033" publication-type="journal">
<string-name>
<surname>Ehrlich</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Humpel</surname>
<given-names>C</given-names>
</string-name>. <article-title>Platelets in psychiatric disorders</article-title>. <source xml:lang="en"/>World J Psychiatry. <year>2012</year>;<volume>2</volume>:<fpage>91</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">24175174</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0034">
<label>34</label>
<mixed-citation id="rth212239-cit-0034" publication-type="journal">
<string-name>
<surname>Pluta</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Ułamek‐Kozioł</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Januszewski</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Czuczwar</surname>
<given-names>SJ</given-names>
</string-name>. <article-title>Platelets, lymphocytes and erythrocytes from Alzheimer's disease patients: the quest for blood cell‐based biomarkers</article-title>. <source xml:lang="en"/>Folia Neuropathol. <year>2018</year>;<volume>56</volume>:<fpage>14</fpage>–<lpage>20</lpage>.<pub-id pub-id-type="pmid">29663736</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0035">
<label>35</label>
<mixed-citation id="rth212239-cit-0035" publication-type="journal">
<string-name>
<surname>Piven</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Tsai</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Nehme</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Coyle</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Chase</surname>
<given-names>GA</given-names>
</string-name>, <string-name>
<surname>Folstein</surname>
<given-names>SE</given-names>
</string-name>. <article-title>Platelet serotonin, a possible marker for familial autism</article-title>. <source xml:lang="en"/>J Autism Dev Disord. <year>1991</year>;<volume>21</volume>:<fpage>51</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">2037549</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0036">
<label>36</label>
<mixed-citation id="rth212239-cit-0036" publication-type="journal">
<string-name>
<surname>Blair</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Flaumenhaft</surname>
<given-names>R</given-names>
</string-name>. <article-title>Platelet α‐granules: basic biology and clinical correlates</article-title>. <source xml:lang="en"/>Blood Rev. <year>2009</year>;<volume>23</volume>:<fpage>177</fpage>–<lpage>89</lpage>.<pub-id pub-id-type="pmid">19450911</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0037">
<label>37</label>
<mixed-citation id="rth212239-cit-0037" publication-type="journal">
<string-name>
<surname>Sharda</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Flaumenhaft</surname>
<given-names>R</given-names>
</string-name>. <article-title>The life cycle of platelet granules</article-title>. <source xml:lang="en"/>F1000Res. <year>2018</year>;<volume>7</volume>:<fpage>236</fpage>.<pub-id pub-id-type="pmid">29560259</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0038">
<label>38</label>
<mixed-citation id="rth212239-cit-0038" publication-type="journal">
<string-name>
<surname>Albers</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Cvejic</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Favier</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Bouwmans</surname>
<given-names>EE</given-names>
</string-name>, <string-name>
<surname>Alessi</surname>
<given-names>M‐C</given-names>
</string-name>, <string-name>
<surname>Bertone</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome</article-title>. <source xml:lang="en"/>Nat Genet. <year>2011</year>;<volume>43</volume>:<fpage>735</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">21765411</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0039">
<label>39</label>
<mixed-citation id="rth212239-cit-0039" publication-type="journal">
<string-name>
<surname>Huizing</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Anikster</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Gahl</surname>
<given-names>WA</given-names>
</string-name>. <article-title>Hermansky‐Pudlak syndrome and Chediak‐Higashi syndrome: disorders of vesicle formation and trafficking</article-title>. <source xml:lang="en"/>Thromb Haemost. <year>2001</year>;<volume>86</volume>:<fpage>233</fpage>–<lpage>45</lpage>.<pub-id pub-id-type="pmid">11487012</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0040">
<label>40</label>
<mixed-citation id="rth212239-cit-0040" publication-type="journal">
<string-name>
<surname>Cullinane</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Schäffer</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Huizing</surname>
<given-names>M</given-names>
</string-name>. <article-title>The BEACH is hot: a LYST of emerging roles for BEACH‐domain containing proteins in human disease</article-title>. <source xml:lang="en"/>Traffic. <year>2013</year>;<volume>14</volume>:<fpage>749</fpage>–<lpage>66</lpage>.<pub-id pub-id-type="pmid">23521701</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0041">
<label>41</label>
<mixed-citation id="rth212239-cit-0041" publication-type="journal">
<string-name>
<surname>Smith</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Woodroffe</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Holguin</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Martinez</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Filipek</surname>
<given-names>PA</given-names>
</string-name>, et al. <article-title>Molecular genetic delineation of a deletion of chromosome 13q12→q13 in a patient with autism and auditory processing deficits</article-title>. <source xml:lang="en"/>Cytogenet Genome Res. <year>2002</year>;<volume>98</volume>:<fpage>233</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">12826745</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0042">
<label>42</label>
<mixed-citation id="rth212239-cit-0042" publication-type="journal">
<string-name>
<surname>Barrett</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Beck</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Bernier</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Bisson</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Braun</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Casavant</surname>
<given-names>TL</given-names>
</string-name>, et al. <article-title>An autosomal genomic screen for autism. Collaborative linkage study of autism</article-title>. <source xml:lang="en"/>Am J Med Genet. <year>1999</year>;<volume>88</volume>:<fpage>609</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="pmid">10581478</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0043">
<label>43</label>
<mixed-citation id="rth212239-cit-0043" publication-type="journal">
<string-name>
<surname>Nuytens</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Gantois</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Stijnen</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Iscru</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Laeremans</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Serneels</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Haploinsufficiency of the autism candidate gene Neurobeachin induces autism‐like behaviors and affects cellular and molecular processes of synaptic plasticity in mice</article-title>. <source xml:lang="en"/>Neurobiol Dis. <year>2013</year>;<volume>51</volume>:<fpage>144</fpage>–<lpage>51</lpage>.<pub-id pub-id-type="pmid">23153818</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0044">
<label>44</label>
<mixed-citation id="rth212239-cit-0044" publication-type="journal">
<string-name>
<surname>Castermans</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Wilquet</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Parthoens</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Huysmans</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Steyaert</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Swinnen</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>The neurobeachin gene is disrupted by a translocation in a patient with idiopathic autism</article-title>. <source xml:lang="en"/>J Med Genet. <year>2003</year>;<volume>40</volume>:<fpage>352</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">12746398</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0045">
<label>45</label>
<mixed-citation id="rth212239-cit-0045" publication-type="journal">
<string-name>
<surname>Castermans</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Volders</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Crepel</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Backx</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>De Vos</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Freson</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>SCAMP5, NBEA and AMISYN: three candidate genes for autism involved in secretion of large dense‐core vesicles</article-title>. <source xml:lang="en"/>Hum Mol Genet. <year>2010</year>;<volume>19</volume>:<fpage>1368</fpage>–<lpage>78</lpage>.<pub-id pub-id-type="pmid">20071347</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0046">
<label>46</label>
<mixed-citation id="rth212239-cit-0046" publication-type="journal">
<string-name>
<surname>Volders</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Nuytens</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Creemers</surname>
<given-names>JW</given-names>
</string-name>. <article-title>The autism candidate gene neurobeachin encodes a scaffolding protein implicated in membrane trafficking and signaling</article-title>. <source xml:lang="en"/>Curr Mol Med. <year>2011</year>;<volume>11</volume>:<fpage>204</fpage>–<lpage>17</lpage>.<pub-id pub-id-type="pmid">21375492</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0047">
<label>47</label>
<mixed-citation id="rth212239-cit-0047" publication-type="journal">
<string-name>
<surname>Nuytens</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Tuand</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Di Michele</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Boonen</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Waelkens</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Freson</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Platelets of mice heterozygous for neurobeachin, a candidate gene for autism spectrum disorder, display protein changes related to aberrant protein kinase A activity</article-title>. <source xml:lang="en"/>Mol Autism. <year>2013</year>;<volume>4</volume>:<fpage>43</fpage>.<pub-id pub-id-type="pmid">24188528</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0048">
<label>48</label>
<mixed-citation id="rth212239-cit-0048" publication-type="journal">
<string-name>
<surname>Mulhern</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Stumpel</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Stong</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Brunner</surname>
<given-names>HG</given-names>
</string-name>, <string-name>
<surname>Bier</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Lippa</surname>
<given-names>N</given-names>
</string-name>; <collab collab-type="authors">CAUSES study</collab>
, <string-name>
<surname>Lopez‐Rangel</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Houcinat</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Barth</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>den Hollander</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Hoffer</surname>
<given-names>MJV</given-names>
</string-name>, et al. <article-title>NBEA: developmental disease gene with early generalized epilepsy phenotypes</article-title>. <source xml:lang="en"/>Ann Neurol. <year>2018</year>;<volume>84</volume>:<fpage>788</fpage>–<lpage>95</lpage>.<pub-id pub-id-type="pmid">30269351</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0049">
<label>49</label>
<mixed-citation id="rth212239-cit-0049" publication-type="journal">
<string-name>
<surname>Gabriele</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Sacco</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Persico</surname>
<given-names>AM</given-names>
</string-name>. <article-title>Blood serotonin levels in autism spectrum disorder : a systematic review and meta‐analysis</article-title>. <source xml:lang="en"/>Eur Neuropsychopharmacol. <year>2014</year>;<volume>24</volume>:<fpage>919</fpage>–<lpage>29</lpage>.<pub-id pub-id-type="pmid">24613076</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0050">
<label>50</label>
<mixed-citation id="rth212239-cit-0050" publication-type="journal">
<string-name>
<surname>Pagan</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Delorme</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Callebert</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Goubran‐Botros</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Amsellem</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Drouot</surname>
<given-names>X</given-names>
</string-name>, et al. <article-title>The serotonin‐N‐acetylserotonin–melatonin pathway as a biomarker for autism spectrum disorders</article-title>. <source xml:lang="en"/>Transl Psychiatry. <year>2014</year>;<volume>4</volume>:<fpage>e479</fpage>–<lpage>e479</lpage>.<pub-id pub-id-type="pmid">25386956</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0051">
<label>51</label>
<mixed-citation id="rth212239-cit-0051" publication-type="journal">
<string-name>
<surname>Lee</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>Simpson</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>B‐H</given-names>
</string-name>, <string-name>
<surname>Yao</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Foer</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Sullivan</surname>
<given-names>B</given-names>
</string-name>, et al. <article-title>Measurement of plasma, serum, and platelet serotonin in individuals with high bone mass and mutations in LRP5</article-title>. <source xml:lang="en"/>J Bone Miner Res. <year>2014</year>;<volume>29</volume>:<fpage>976</fpage>–<lpage>81</lpage>.<pub-id pub-id-type="pmid">24038240</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0052">
<label>52</label>
<mixed-citation id="rth212239-cit-0052" publication-type="journal">
<string-name>
<surname>Maurer‐Spurej</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Pittendreigh</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Misri</surname>
<given-names>S</given-names>
</string-name>. <article-title>Platelet serotonin levels support depression scores for women with postpartum depression</article-title>. <source xml:lang="en"/>J Psychiatry Neurosci. <year>2007</year>;<volume>32</volume>:<fpage>23</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">17245471</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0053">
<label>53</label>
<mixed-citation id="rth212239-cit-0053" publication-type="journal">
<string-name>
<surname>Fouassier</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bourgerette</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Libert</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Pouplard</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Marques‐Verdier</surname>
<given-names>A</given-names>
</string-name>. <article-title>Determination of serotonin release from platelets by HPLC and ELISA in the diagnosis of heparin‐induced thrombocytopenia: comparison with reference method by [14C]‐serotonin release assay</article-title>. <source xml:lang="en"/>J Thromb Haemost. <year>2006</year>;<volume>4</volume>:<fpage>1136</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">16689769</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0054">
<label>54</label>
<mixed-citation id="rth212239-cit-0054" publication-type="journal">
<string-name>
<surname>Marazziti</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Muratori</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Cesari</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Masala</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Baroni</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Giannaccini</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>Increased density of the platelet serotonin transporter in autism</article-title>. <source xml:lang="en"/>Pharmacopsychiatry. <year>2000</year>;<volume>33</volume>:<fpage>165</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">11071017</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0055">
<label>55</label>
<mixed-citation id="rth212239-cit-0055" publication-type="journal">
<string-name>
<surname>Sutcliffe</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Delahanty</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Prasad</surname>
<given-names>HC</given-names>
</string-name>, <string-name>
<surname>McCauley</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Han</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Jiang</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Allelic heterogeneity at the serotonin transporter locus (SLC6A4) confers susceptibility to autism and rigid‐compulsive behaviors</article-title>. <source xml:lang="en"/>Am J Hum Genet. <year>2005</year>;<volume>77</volume>:<fpage>265</fpage>–<lpage>79</lpage>.<pub-id pub-id-type="pmid">15995945</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0056">
<label>56</label>
<mixed-citation id="rth212239-cit-0056" publication-type="journal">
<string-name>
<surname>Veenstra‐VanderWeele</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Muller</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Iwamoto</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Sauer</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Owens</surname>
<given-names>WA</given-names>
</string-name>, <string-name>
<surname>Shah</surname>
<given-names>CR</given-names>
</string-name>, et al. <article-title>Autism gene variant causes hyperserotonemia, serotonin receptor hypersensitivity, social impairment and repetitive behavior</article-title>. <source xml:lang="en"/>Proc Natl Acad Sci U S A. <year>2012</year>;<volume>109</volume>:<fpage>5469</fpage>–<lpage>74</lpage>.<pub-id pub-id-type="pmid">22431635</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0057">
<label>57</label>
<mixed-citation id="rth212239-cit-0057" publication-type="journal">
<string-name>
<surname>Napolioni</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Lombardi</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Sacco</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Curatolo</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Manzi</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Alessandrelli</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Family‐based association study of ITGB3 in autism spectrum disorder and its endophenotypes</article-title>. <source xml:lang="en"/>Eur J Hum Genet. <year>2011</year>;<volume>19</volume>:<fpage>353</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">21102624</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0058">
<label>58</label>
<mixed-citation id="rth212239-cit-0058" publication-type="journal">
<string-name>
<surname>Dohn</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Kooker</surname>
<given-names>CG</given-names>
</string-name>, <string-name>
<surname>Bastarache</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Jessen</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Rinaldi</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Varney</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>The gain‐of‐function integrin β3 Pro33 variant alters the serotonin system in the mouse</article-title>. <source xml:lang="en"/>Brain. <year>2017</year>;<volume>37</volume>:<fpage>11271</fpage>–<lpage>84</lpage>.</mixed-citation>
</ref>
<ref id="rth212239-bib-0059">
<label>59</label>
<mixed-citation id="rth212239-cit-0059" publication-type="journal">
<string-name>
<surname>Bijl</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Thys</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Wittevrongel</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>De la Marche</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Devriendt</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Peeters</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>Platelet studies in autism spectrum disorder patients and first‐degree relatives</article-title>. <source xml:lang="en"/>Mol Autism. <year>2015</year>;<volume>6</volume>:<fpage>57</fpage>.<pub-id pub-id-type="pmid">26500752</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0060">
<label>60</label>
<mixed-citation id="rth212239-cit-0060" publication-type="journal">
<string-name>
<surname>McBride</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Anderson</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Hertzig</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Snow</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Thompson</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Khait</surname>
<given-names>VD</given-names>
</string-name>, et al. <article-title>Effects of diagnosis, race, and puberty on platelet serotonin levels in autism and mental retardation</article-title>. <source xml:lang="en"/>J Am Acad Child Adolesc Psychiatry. <year>1998</year>;<volume>37</volume>:<fpage>767</fpage>–<lpage>76</lpage>.<pub-id pub-id-type="pmid">9666633</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0061">
<label>61</label>
<mixed-citation id="rth212239-cit-0061" publication-type="journal">
<string-name>
<surname>Nurden</surname>
<given-names>AT</given-names>
</string-name>. <article-title>Should studies on Glanzmann thrombasthenia not be telling us more about cardiovascular disease and other major illnesses?</article-title>
<source xml:lang="en"/>Blood Rev. <year>2017</year>;<volume>31</volume>:<fpage>287</fpage>–<lpage>99</lpage>.<pub-id pub-id-type="pmid">28395882</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0062">
<label>62</label>
<mixed-citation id="rth212239-cit-0062" publication-type="journal">
<string-name>
<surname>Thomas</surname>
<given-names>SG</given-names>
</string-name>. <article-title>The structure of resting and activated platelets</article-title>. <source xml:lang="en"/>Platelets. <year>2019</year>;<fpage>47</fpage>–<lpage>77</lpage>.</mixed-citation>
</ref>
<ref id="rth212239-bib-0063">
<label>63</label>
<mixed-citation id="rth212239-cit-0063" publication-type="journal">
<string-name>
<surname>Gabriele</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Canali</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lintas</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Sacco</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Tirindelli</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Ricciardello</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Evidence that ITGB3 promoter variants increase serotonin blood levels by regulating platelet serotonin transporter trafficking</article-title>. <source xml:lang="en"/>Hum Mol Genet. <year>2019</year>;<volume>28</volume>:<fpage>1153</fpage>–<lpage>61</lpage>.<pub-id pub-id-type="pmid">30535103</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0064">
<label>64</label>
<mixed-citation id="rth212239-cit-0064" publication-type="journal">
<string-name>
<surname>Schuch</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Muller</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Endres</surname>
<given-names>RG</given-names>
</string-name>, <string-name>
<surname>Bosa</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Longo</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Schuler‐Faccini</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>The role of β3 integrin gene variants in autism spectrum disorders — diagnosis and symptomatology</article-title>. <source xml:lang="en"/>Gene. <year>2014</year>;<volume>553</volume>:<fpage>24</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="pmid">25280596</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0065">
<label>65</label>
<mixed-citation id="rth212239-cit-0065" publication-type="journal">
<string-name>
<surname>Yip</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Montgomery</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Siu</surname>
<given-names>CH</given-names>
</string-name>. <article-title>The Arg‐Gly‐Asp motif in the cell adhesion molecule L1 promotes neurite outgrowth via interaction with the alphavbeta3 integrin</article-title>. <source xml:lang="en"/>Mol Biol Cell. <year>1998</year>;<volume>9</volume>:<fpage>277</fpage>–<lpage>90</lpage>.<pub-id pub-id-type="pmid">9450954</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0066">
<label>66</label>
<mixed-citation id="rth212239-cit-0066" publication-type="journal">
<string-name>
<surname>Carneiro</surname>
<given-names>AMD</given-names>
</string-name>, <string-name>
<surname>Cook</surname>
<given-names>EH</given-names>
</string-name>, <string-name>
<surname>Murphy</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Blakely</surname>
<given-names>RD</given-names>
</string-name>. <article-title>Interactions between integrin αIIbβ3 and the serotonin transporter regulate serotonin transport and platelet aggregation in mice and humans</article-title>. <source xml:lang="en"/>J Clin Invest. <year>2008</year>;<volume>118</volume>:<fpage>1544</fpage>–<lpage>52</lpage>.<pub-id pub-id-type="pmid">18317590</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0067">
<label>67</label>
<mixed-citation id="rth212239-cit-0067" publication-type="journal">
<string-name>
<surname>Whyte</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Jessen</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Varney</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Carneiro</surname>
<given-names>AMD</given-names>
</string-name>. <article-title>Serotonin transporter and integrin beta 3 genes interact to modulate serotonin uptake in mouse brain</article-title>. <source xml:lang="en"/>Neurochem Int. <year>2014</year>;<volume>73</volume>:<fpage>122</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">24083985</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0068">
<label>68</label>
<mixed-citation id="rth212239-cit-0068" publication-type="journal">
<string-name>
<surname>Carter</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Shah</surname>
<given-names>CR</given-names>
</string-name>, <string-name>
<surname>Muller</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Crawley</surname>
<given-names>JN</given-names>
</string-name>, <string-name>
<surname>Carneiro</surname>
<given-names>AMD</given-names>
</string-name>, <string-name>
<surname>Veenstra‐VanderWeele</surname>
<given-names>J</given-names>
</string-name>. <article-title>Absence of preference for social novelty and increased grooming in integrin β3 knockout mice: initial studies and future directions</article-title>. <source xml:lang="en"/>Autism Res. <year>2011</year>;<volume>4</volume>:<fpage>57</fpage>–<lpage>67</lpage>.<pub-id pub-id-type="pmid">21254450</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0069">
<label>69</label>
<mixed-citation id="rth212239-cit-0069" publication-type="journal">
<string-name>
<surname>Nurden</surname>
<given-names>AT</given-names>
</string-name>, <string-name>
<surname>Fiore</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Nurden</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Pillois</surname>
<given-names>X</given-names>
</string-name>. <article-title>Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models</article-title>. <source xml:lang="en"/>Blood. <year>2011</year>;<volume>118</volume>:<fpage>5996</fpage>–<lpage>6005</lpage>.<pub-id pub-id-type="pmid">21917754</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0070">
<label>70</label>
<mixed-citation id="rth212239-cit-0070" publication-type="journal">
<string-name>
<surname>Ruan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Schmugge</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Clemetson</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Cazes</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Combrie</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Bourre</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Homozygous Cys542Arg substitution in GPIIIa in a Swiss patient with type I Glanzmann's thrombasthenia</article-title>. <source xml:lang="en"/>Br J Haematol. <year>1999</year>;<volume>105</volume>:<fpage>523</fpage>–<lpage>31</lpage>.<pub-id pub-id-type="pmid">10233432</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0071">
<label>71</label>
<mixed-citation id="rth212239-cit-0071" publication-type="journal">
<string-name>
<surname>Ruiz</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>CY</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>QH</given-names>
</string-name>, <string-name>
<surname>Sigaud‐Fiks</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fressinaud</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Muller</surname>
<given-names>JY</given-names>
</string-name>, et al. <article-title>A point mutation in the cysteine‐rich domain of glycoprotein (GP) IIIa results in the expression of a GPIIb‐IIIa (alphaIIbbeta3) integrin receptor locked in a high‐affinity state and a Glanzmann thrombasthenia‐like phenotype</article-title>. <source xml:lang="en"/>Blood. <year>2001</year>;<volume>98</volume>:<fpage>2432</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="pmid">11588040</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0072">
<label>72</label>
<mixed-citation id="rth212239-cit-0072" publication-type="journal">
<string-name>
<surname>Holinstat</surname>
<given-names>M</given-names>
</string-name>. <article-title>Normal platelet function</article-title>. <source xml:lang="en"/>Cancer Metastasis Rev. <year>2017</year>;<volume>36</volume>:<fpage>195</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">28667366</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0073">
<label>73</label>
<mixed-citation id="rth212239-cit-0073" publication-type="journal">
<string-name>
<surname>Safai‐Kutti</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Denfors</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Kutti</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wadenvik</surname>
<given-names>H</given-names>
</string-name>. <article-title>In vitro platelet function in infantile autism</article-title>. <source xml:lang="en"/>Folia Haematol Int Mag Klin Morphol Blutforsch. <year>1988</year>;<volume>115</volume>:<fpage>897</fpage>–<lpage>901</lpage>.<pub-id pub-id-type="pmid">2467861</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0074">
<label>74</label>
<mixed-citation id="rth212239-cit-0074" publication-type="journal">
<string-name>
<surname>Hranilović</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Bujas‐Petković</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Tomičić</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bordukalo‐Nikšić</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Blažević</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Čičin‐Šain</surname>
<given-names>L</given-names>
</string-name>. <article-title>Hyperserotonemia in autism: activity of 5HT‐associated platelet proteins</article-title>. <source xml:lang="en"/>J Neural Transm. <year>2009</year>;<volume>116</volume>:<fpage>493</fpage>–<lpage>501</lpage>.<pub-id pub-id-type="pmid">19221690</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0075">
<label>75</label>
<mixed-citation id="rth212239-cit-0075" publication-type="journal">
<string-name>
<surname>Pagan</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Goubran‐Botros</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Delorme</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Benabou</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lemière</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Murray</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Disruption of melatonin synthesis is associated with impaired 14‐3‐3 and miR‐451 levels in patients with autism spectrum disorders</article-title>. <source xml:lang="en"/>Sci Rep. <year>2017</year>;<volume>7</volume>:<fpage>2096</fpage>.<pub-id pub-id-type="pmid">28522826</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0076">
<label>76</label>
<mixed-citation id="rth212239-cit-0076" publication-type="journal">
<string-name>
<surname>Erren</surname>
<given-names>TC</given-names>
</string-name>, <string-name>
<surname>Reiter</surname>
<given-names>RJ</given-names>
</string-name>. <article-title>Melatonin: a universal time messenger</article-title>. <source xml:lang="en"/>Neuro Endocrinol Lett. <year>2015</year>;<volume>36</volume>:<fpage>187</fpage>–<lpage>92</lpage>.<pub-id pub-id-type="pmid">26313381</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0077">
<label>77</label>
<mixed-citation id="rth212239-cit-0077" publication-type="journal">
<string-name>
<surname>Benabou</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rolland</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Leblond</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>Millot</surname>
<given-names>GA</given-names>
</string-name>, <string-name>
<surname>Huguet</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Delorme</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Heritability of the melatonin synthesis variability in autism spectrum disorders</article-title>. <source xml:lang="en"/>Sci Rep. <year>2017</year>;<volume>7</volume>:<fpage>17746</fpage>.<pub-id pub-id-type="pmid">29255243</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0078">
<label>78</label>
<mixed-citation id="rth212239-cit-0078" publication-type="journal">
<string-name>
<surname>Sompol</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Baba</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Paul</surname>
<given-names>KN</given-names>
</string-name>, <string-name>
<surname>Tosini</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Iuvone</surname>
<given-names>PM</given-names>
</string-name>, et al. <article-title>N‐acetylserotonin promotes hippocampal neuroprogenitor cell proliferation in sleep‐deprived mice</article-title>. <source xml:lang="en"/>Proc Natl Acad Sci U S A. <year>2011</year>;<volume>108</volume>:<fpage>8844</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">21555574</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0079">
<label>79</label>
<mixed-citation id="rth212239-cit-0079" publication-type="journal">
<string-name>
<surname>Choudhury</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Singh</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Palit</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Shukla</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ganguly</surname>
<given-names>S</given-names>
</string-name>. <article-title>Administration of N‐acetylserotonin and melatonin alleviate chronic ketamine‐induced behavioural phenotype accompanying BDNF‐independent and dependent converging cytoprotective mechanisms in the hippocampus</article-title>. <source xml:lang="en"/>Behav Brain Res. <year>2016</year>;<volume>297</volume>:<fpage>204</fpage>–<lpage>12</lpage>.<pub-id pub-id-type="pmid">26475510</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0080">
<label>80</label>
<mixed-citation id="rth212239-cit-0080" publication-type="journal">
<string-name>
<surname>Schafer</surname>
<given-names>ST</given-names>
</string-name>, <string-name>
<surname>Paquola</surname>
<given-names>ACM</given-names>
</string-name>, <string-name>
<surname>Stern</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Gosselin</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Ku</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pena</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Pathological priming causes developmental gene network heterochronicity in autistic subject‐derived neurons</article-title>. <source xml:lang="en"/>Nat Neurosci. <year>2019</year>;<volume>22</volume>:<fpage>243</fpage>–<lpage>55</lpage>.<pub-id pub-id-type="pmid">30617258</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0081">
<label>81</label>
<mixed-citation id="rth212239-cit-0081" publication-type="journal">
<string-name>
<surname>Lake</surname>
<given-names>CR</given-names>
</string-name>, <string-name>
<surname>Ziegler</surname>
<given-names>MG</given-names>
</string-name>, <string-name>
<surname>Murphy</surname>
<given-names>DL</given-names>
</string-name>. <article-title>Increased norepinephrine levels and decreased dopamine‐beta‐hydroxylase activity in primary autism</article-title>. <source xml:lang="en"/>Arch Gen Psychiatry. <year>1977</year>;<volume>34</volume>:<fpage>553</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">558741</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0082">
<label>82</label>
<mixed-citation id="rth212239-cit-0082" publication-type="journal">
<string-name>
<surname>Launay</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Bursztejn</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Ferrari</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Dreux</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Braconnier</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Zarifian</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Catecholamines metabolism in infantile autism: a controlled study of 22 autistic children</article-title>. <source xml:lang="en"/>J Autism Dev Disord. <year>1987</year>;<volume>17</volume>:<fpage>333</fpage>–<lpage>47</lpage>.<pub-id pub-id-type="pmid">3654486</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0083">
<label>83</label>
<mixed-citation id="rth212239-cit-0083" publication-type="journal">
<string-name>
<surname>Khalifa</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Shahin</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Salem</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Raafat</surname>
<given-names>O</given-names>
</string-name>. <article-title>Serum glutamate was elevated in children aged 3‐10 years with autism spectrum disorders when they were compared with controls</article-title>. <source xml:lang="en"/>Acta Paediatr. <year>2019</year>;<volume>108</volume>:<fpage>295</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">29949195</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0084">
<label>84</label>
<mixed-citation id="rth212239-cit-0084" publication-type="journal">
<string-name>
<surname>Morrell</surname>
<given-names>CN</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Ikeda</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Beique</surname>
<given-names>J‐C</given-names>
</string-name>, <string-name>
<surname>Swaim</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Mason</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Glutamate mediates platelet activation through the AMPA receptor</article-title>. <source xml:lang="en"/>J Exp Med. <year>2008</year>;<volume>205</volume>:<fpage>575</fpage>–<lpage>84</lpage>.<pub-id pub-id-type="pmid">18283118</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0085">
<label>85</label>
<mixed-citation id="rth212239-cit-0085" publication-type="journal">
<string-name>
<surname>Kasatkina</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Borisova</surname>
<given-names>TA</given-names>
</string-name>. <article-title>Glutamate release from platelets: exocytosis versus glutamate transporter reversal</article-title>. <source xml:lang="en"/>Int J Biochem Cell Biol. <year>2013</year>;<volume>45</volume>:<fpage>2585</fpage>–<lpage>95</lpage>.<pub-id pub-id-type="pmid">23994539</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0086">
<label>86</label>
<mixed-citation id="rth212239-cit-0086" publication-type="journal">
<string-name>
<surname>Kaneez</surname>
<given-names>FS</given-names>
</string-name>, <string-name>
<surname>Saeed</surname>
<given-names>SA</given-names>
</string-name>. <article-title>Investigating GABA and its function in platelets as compared to neurons</article-title>. <source xml:lang="en"/>Platelets. <year>2009</year>;<volume>20</volume>:<fpage>328</fpage>–<lpage>33</lpage>.<pub-id pub-id-type="pmid">19637096</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0087">
<label>87</label>
<mixed-citation id="rth212239-cit-0087" publication-type="journal">
<string-name>
<surname>Rolf</surname>
<given-names>LH</given-names>
</string-name>, <string-name>
<surname>Haarmann</surname>
<given-names>FY</given-names>
</string-name>, <string-name>
<surname>Grotemeyer</surname>
<given-names>KH</given-names>
</string-name>, <string-name>
<surname>Kehrer</surname>
<given-names>H</given-names>
</string-name>. <article-title>Serotonin and amino acid content in platelets of autistic children</article-title>. <source xml:lang="en"/>Acta Psychiatr Scand. <year>1993</year>;<volume>87</volume>:<fpage>312</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">8517170</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0088">
<label>88</label>
<mixed-citation id="rth212239-cit-0088" publication-type="journal">
<string-name>
<surname>Shimmura</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Suda</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tsuchiya</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Hashimoto</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ohno</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Matsuzaki</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>Alteration of plasma glutamate and glutamine levels in children with high‐functioning autism</article-title>. <source xml:lang="en"/>PLoS One. <year>2011</year>;<volume>6</volume>:<fpage>e25340</fpage>.<pub-id pub-id-type="pmid">21998651</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0089">
<label>89</label>
<mixed-citation id="rth212239-cit-0089" publication-type="journal">
<string-name>
<surname>Dhossche</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Applegate</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Abraham</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Maertens</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Bland</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Bencsath</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Elevated plasma gamma‐aminobutyric acid (GABA) levels in autistic youngsters: stimulus for a GABA hypothesis of autism</article-title>. <source xml:lang="en"/>Med Sci Monit. <year>2002</year>;<volume>8</volume>:<fpage>PR1‐6</fpage>.</mixed-citation>
</ref>
<ref id="rth212239-bib-0090">
<label>90</label>
<mixed-citation id="rth212239-cit-0090" publication-type="journal">
<string-name>
<surname>Spivak</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Golubchik</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Mozes</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Vered</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Nechmad</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Weizman</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Low platelet‐poor plasma levels of serotonin in adult autistic patients</article-title>. <source xml:lang="en"/>Neuropsychobiology. <year>2004</year>;<volume>50</volume>:<fpage>157</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="pmid">15292671</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0091">
<label>91</label>
<mixed-citation id="rth212239-cit-0091" publication-type="journal">
<string-name>
<surname>Connors</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Matteson</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Sega</surname>
<given-names>GA</given-names>
</string-name>, <string-name>
<surname>Lozzio</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Carroll</surname>
<given-names>RC</given-names>
</string-name>, <string-name>
<surname>Zimmerman</surname>
<given-names>AW</given-names>
</string-name>. <article-title>Plasma serotonin in autism</article-title>. <source xml:lang="en"/>Pediatr Neurol. <year>2006</year>;<volume>35</volume>:<fpage>182</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">16939857</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0092">
<label>92</label>
<mixed-citation id="rth212239-cit-0092" publication-type="journal">
<string-name>
<surname>Hranilovic</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Bujas‐Petkovic</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Vragovic</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Vuk</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hock</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Jernej</surname>
<given-names>B</given-names>
</string-name>. <article-title>Hyperserotonemia in adults with autistic disorder</article-title>. <source xml:lang="en"/>J Autism Dev Disord. <year>2007</year>;<volume>37</volume>:<fpage>1934</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="pmid">17165147</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0093">
<label>93</label>
<mixed-citation id="rth212239-cit-0093" publication-type="journal">
<string-name>
<surname>Coutinho</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Sousa</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Martins</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Correia</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Morgadinho</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Bento</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Evidence for epistasis between SLC6A4 and ITGB3 in autism etiology and in the determination of platelet serotonin levels</article-title>. <source xml:lang="en"/>Hum Genet. <year>2007</year>;<volume>121</volume>:<fpage>243</fpage>–<lpage>56</lpage>.<pub-id pub-id-type="pmid">17203304</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0094">
<label>94</label>
<mixed-citation id="rth212239-cit-0094" publication-type="journal">
<string-name>
<surname>Kemperman</surname>
<given-names>RFJ</given-names>
</string-name>, <string-name>
<surname>Muskiet</surname>
<given-names>FD</given-names>
</string-name>, <string-name>
<surname>Boutier</surname>
<given-names>AI</given-names>
</string-name>, <string-name>
<surname>Kema</surname>
<given-names>IP</given-names>
</string-name>, <string-name>
<surname>Muskiet</surname>
<given-names>FAJ</given-names>
</string-name>. <article-title>Brief report: normal intestinal permeability at elevated platelet serotonin levels in a subgroup of children with pervasive developmental disorders in Curaçao (The Netherlands Antilles)</article-title>. <source xml:lang="en"/>J Autism Dev Disord. <year>2008</year>;<volume>38</volume>:<fpage>401</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">17661166</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0095">
<label>95</label>
<mixed-citation id="rth212239-cit-0095" publication-type="journal">
<string-name>
<surname>Hranilović</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Novak</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Babić</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Novokmet</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bujas‐Petković</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Jernej</surname>
<given-names>B</given-names>
</string-name>. <article-title>Hyperserotonemia in autism: the potential role of 5HT‐related gene variants</article-title>. <source xml:lang="en"/>Coll Antropol. <year>2008</year>;<volume>32</volume>(<issue>Suppl 1</issue>):<fpage>75</fpage>–<lpage>80</lpage>.</mixed-citation>
</ref>
<ref id="rth212239-bib-0096">
<label>96</label>
<mixed-citation id="rth212239-cit-0096" publication-type="journal">
<string-name>
<surname>Mostafa</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>AL‐Ayadhi</surname>
<given-names>L</given-names>
</string-name>. <article-title>A lack of association between hyperserotonemia and the increased frequency of serum anti‐myelin basic protein auto‐antibodies in autistic children</article-title>. <source xml:lang="en"/>J Neuroinflammation. <year>2011</year>;<volume>8</volume>:<fpage>71</fpage>.<pub-id pub-id-type="pmid">21696608</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0097">
<label>97</label>
<mixed-citation id="rth212239-cit-0097" publication-type="journal">
<string-name>
<surname>Anderson</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Hertzig</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>McBride</surname>
<given-names>PA</given-names>
</string-name>. <article-title>Brief report: platelet‐poor plasma serotonin in autism</article-title>. <source xml:lang="en"/>J Autism Dev Disord. <year>2012</year>;<volume>42</volume>:<fpage>1510</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">21979109</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0098">
<label>98</label>
<mixed-citation id="rth212239-cit-0098" publication-type="journal">
<string-name>
<surname>Chakraborti</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Verma</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Karmakar</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Jaiswal</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Sanyal</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Paul</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Genetic variants of MAOB affect serotonin level and specific behavioral attributes to increase autism spectrum disorder (ASD) susceptibility in males</article-title>. <source xml:lang="en"/>Prog Neuropsychopharmacol Biol Psychiatry. <year>2016</year>;<volume>71</volume>:<fpage>123</fpage>–<lpage>36</lpage>.<pub-id pub-id-type="pmid">27381555</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0099">
<label>99</label>
<mixed-citation id="rth212239-cit-0099" publication-type="journal">
<string-name>
<surname>Marler</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ferguson</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>EB</given-names>
</string-name>, <string-name>
<surname>Peters</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Williams</surname>
<given-names>KC</given-names>
</string-name>, <string-name>
<surname>McDonnell</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Brief report: whole blood serotonin levels and gastrointestinal symptoms in autism spectrum disorder</article-title>. <source xml:lang="en"/>J Autism Dev Disord. <year>2016</year>;<volume>46</volume>:<fpage>1124</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="pmid">26527110</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0100">
<label>100</label>
<mixed-citation id="rth212239-cit-0100" publication-type="journal">
<string-name>
<surname>Shuffrey</surname>
<given-names>LC</given-names>
</string-name>, <string-name>
<surname>Guter</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Delaney</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Jacob</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Anderson</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Sutcliffe</surname>
<given-names>JS</given-names>
</string-name>, et al. <article-title>Is there sexual dimorphism of hyperserotonemia in autism spectrum disorder?</article-title>
<source xml:lang="en"/>Autism Res. <year>2017</year>;<volume>10</volume>:<fpage>1417</fpage>–<lpage>23</lpage>.<pub-id pub-id-type="pmid">28401654</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0101">
<label>101</label>
<mixed-citation id="rth212239-cit-0101" publication-type="journal">
<string-name>
<surname>Montgomery</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Shuffrey</surname>
<given-names>LC</given-names>
</string-name>, <string-name>
<surname>Guter</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Anderson</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Jacob</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Mosconi</surname>
<given-names>MW</given-names>
</string-name>, et al. <article-title>Maternal serotonin levels are associated with cognitive ability and core symptoms in autism spectrum disorder</article-title>. <source xml:lang="en"/>J Am Acad Child Adolesc Psychiatry. <year>2018</year>;<volume>57</volume>:<fpage>867</fpage>–<lpage>75</lpage>.<pub-id pub-id-type="pmid">30392628</pub-id></mixed-citation>
</ref>
<ref id="rth212239-bib-0102">
<label>102</label>
<mixed-citation id="rth212239-cit-0102" publication-type="journal">
<string-name>
<surname>McBride</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Anderson</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Hertzig</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Sweeney</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Kream</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Cohen</surname>
<given-names>DJ</given-names>
</string-name>, et al. <article-title>Serotonergic responsivity in male young adults with autistic disorder. Results of a pilot study</article-title>. <source xml:lang="en"/>Arch Gen Psychiatry. <year>1989</year>;<volume>46</volume>:<fpage>213</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="pmid">2919950</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>